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ABSTRACT 
In this study primarily response to CDDP administration in terms of cell viability was 
examined. For demonstration of cell viability in response to CDDP treatment, MTT Assay 
was used in the absence or presence of the antioxidant, N-Acetyl-L-Cysteine (NAC) pre-
treatment. It showed around 19% decrease in cell viability for wt and 21% for p53-/- in the 
absence of NAC at 24h and 30µM CDDP. It also revealed around 72% decrease for wt and 
31% decrease for p53-/- in the absence of NAC at 48h and 30µM CDDP, yet in the presence 
of NAC the cell viability was found to be favoured by almost 20% for wt. To assess the 
extend of apoptotic response in the absence or presence of NAC pre-treatment Flow 
Cytometric Analyses by Annexin-V Labelling was applied. It  revealed around 1.6 fold 
increase for wt and 2.4 fold increase for p53-/- in the absence of NAC at 24h and 30µM 
CDDP, yet in the presence of NAC the apoptotic response was found to be repressed by 
almost 20% for wt and 40% for p53-/- It also showed around  4.7 fold increase for wt and 2.6 
fold increase for p53-/- in the absence of NAC at 48h and 30µM CDDP, yet in the presence of 
NAC the apoptotic response was found to be repressed by almost 57% for wt. The data 
showed that wt and p53-/- cells differed in cell viability depending on the dose of CDDP and 
antioxidant pre-treatment, indicating that some fraction of the apoptotic response was due to 
increased ROS levels.  
In addition, DCFH-DA was exploited as the label for ROS in Flow Cytometric Analyses. 
Flow Cytometry showed around 4 fold increase for wt and 3.2 fold increase for p53-/- at 24h 
and 30µM CDDP yet in the presence of NAC the increase of ROS was found to be repressed 
by almost 50% for wt. It also revealed around 5.2 fold increase for wt and 5 fold increase for 
p53-/- in the absence of NAC at 48h and 30µM CDDP, yet in the presence of NAC the 
increase of ROS was found to be repressed by almost 66% for p53-/-.  A second method, 
Thiobarbituric Acid Reactive Substances (TBARS) Assay was used to gain more insight, this 
time in terms of lipid peroxidation. TBARS Assay revealed 8.4 fold increase for wt and 5.9 
fold increase for p53-/- in the absence of NAC at 24h and 30µM CDDP, yet in the presence of 
NAC the increase was found to be repressed by almost 75% for wt. It also showed around 1.5 
fold increase for wt and 1.8 fold increase for p53-/- in the absence of NAC at 48h and 30µM 
CDDP, yet in the presence of NAC the increase was found to be repressed by around 13% for 
wt and 39% for p53-/-. Data acquired in this section indicated increased ROS and lipid 
peroxidation levels with CDDP treatment which could be overcome by NAC pre-treatment. 
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In further experiments, OxyBlot™ procedure was applied to total protein isolates and also to 
the pro-survival proteins of the Bcl-2 family proteins, Bcl-2, Mcl-1 and Bcl-xL, fished out of 
the total protein suspensions via immunoprecipitation. The technique gave the picture of an 
increased protein carbonylation with increasing doses of CDDP (0, 30 and 60µM CDDP) and 
also exhibited that all three pro-survival proteins gave detectable carbonylation signal in the 
absence of the antioxidant and TP53 gene at 30µM CDDP, supporting the initial hypothesis of 
this work that loss of function of pro-survival proteins due to protein modifications 
contributes to apoptotic response in this experimental setup. 
These results were discussed in the light of intracellular signalling cascades, especially those 
related to apoptosis and intracellular oxidative stress. As CDDP was found to be inducing 
apoptosis via affecting the overall redox status of the cell and the concept of sensitization to 
CDDP treatment could be an interesting approach for possible future applications of this 
work. 
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ÖZET 
Bu çalışmada öncelikle, hücrelerin sisplatin uygulamasına canlılık açısından tepkisi incelendi.  
Hücre canlılığını göstermek için, MTT Analizi bir antioksidan olan asetilsisteinin (NAC) ön-
uygulaması yapılarak ve yapılmadan kullanıldı. MTT Analizi 30µM sisplatin NAC olmadan 
24h uygulandığında hücre canlılığında wt için yaklaşık %19 ve p53-/- için yaklaşık %21 
azalma gösterdi. 30µM sisplatin NAC olmadan 48h uygulandığında ise, hücre canlılığında wt 
için yaklaşık %72 ve p53-/- için yaklaşık %31 azalma gösterdi ancak NAC verildiğinde wt 
için 20% artış gözlendi. Sisplatine bağlı apoptotik tepkinin boyutlarını NAC ön-
uygulamasının yapıldığı ve yapılmadığı durumlarda görüntülemek için Annexin-V 
işaretlemesi kullanılarak Akış Sitometrisi kullanıldı. Akış Sitometrisi 30µM sisplatin NAC 
olmadan 24h uygulandığında apoptotik tepkide wt için yaklaşık 1.6 kat ve p53-/- için yaklaşık 
2.4 kat artış gösterdi fakat NAC verildiğinde wt için 20% azalış gözlendi. 30µM sisplatin 
NAC olmadan 48h uygulandığında ise, apoptotik tepkide wt için yaklaşık 4.7 kat ve p53-/- 
için yaklaşık 2.6 kat artış gösterdi fakat NAC verildiğinde wt için 57% azalış gözlendi. Elde 
edilen data wt ve p53-/- hücrelerinin yaşayabilirlikte sisplatin dozu ve antioksidan ön-
uygulamasına bağlı olarak değişiklik gösterdiğini bildirdi. Bu da apoptotik tepkinin bir 
kısmının yükselen ROT seviyeleriyle ilintili olduğunu işaret etti. 
Ek olarak, Akış Sitometrisinde ROT için işaretleyici olarak DCFH-DA kullanıldı. Akış 
Sitometrisi 30µM sisplatin NAC olmadan 24h uygulandığında apoptotik tepkide wt için 
yaklaşık 4 kat ve p53-/- için yaklaşık 3.2 kat artış gösterdi fakat NAC verildiğinde wt için 
50% azalış gözlendi. 30µM sisplatin NAC olmadan 48h uygulandığında ise, apoptotik tepkide 
wt için yaklaşık 5.2 kat ve p53-/- için yaklaşık 5 kat artış gösterdi fakat NAC verildiğinde 
p53-/- için 66% azalış gözlendi. İkinci bir yöntem, Tiyobarbitürik Asit Reaktif Maddeler 
(TBARS) Analizi, özellikle lipid peroksidasyonu hakkında daha fazla bilgi sağlamak üzere 
uygulandı. TBARS Analizi 30µM sisplatin NAC olmadan 24h uygulandığında wt için 
yaklaşık 8.4 kat ve p53-/- için yaklaşık 5.9 kat artış gösterdi fakat NAC verildiğinde wt için 
75% azalış gözlendi. 30µM sisplatin NAC olmadan 48h uygulandığında ise, wt için yaklaşık 
1.5 kat ve p53-/- için yaklaşık 1.8 kat artış gösterdi fakat NAC verildiğinde wt için %13 ve 
p53-/- için %39 azalış gözlendi. Bu bölümde elde edilen data ROT ve lipid peroksidasyonu 
seviyelerinin sisplatin uygulamasına bağlı olarak arttığını ve bunun aktioksidan verilerek geri 
çevrilebildiğini gösterdi. 
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Daha sonraki deneylerde, OxyBlot™ tekniği total protein izolasyonları ve immünçökeltme 
yöntemiyle total protein izolasyonlarından ayıklanmış Bcl-2 ailesi proteinlerinden kalım-
yanlısı Bcl-2, Mcl-1 ve Bcl-xL proteinleri için kullanıldı. Teknik artan sisplatin dozları (0, 20, 
30, 60µM) ile protein karbonilasyonunun arttığını ve 30µM sisplatin ve antioksidan ile TP53 
geninin yokluğu durumunda kalım-yanlısı proteinlerin üçünün de saptanabilir karbonilasyon 
sinyalleri verdiğini gösterdi. Bu da bu çalışmanın başlangıçtaki önsavı olan bu deney 
düzeneğinde kalım-yanlısı proteinlerin protein modifikasyonları nedeniyle işlev kaybına 
uğramalarının apoptotik cevaba katkıda bulunması fikrini destekledi. 
Bu sonuçlar özellikle apoptoz ve hücre içi oksidatif stres bağlantılı sinyal kademeli dizilerinin 
ışığında tartışıldı. Sisplatinin hücrenin genel yükseltgenme-indirgenme durumunu etkilemek 
suretiyle apoptozu indüklediği bulunduğundan sisplatin uygulamasına hassaslaştırılma 
anlayışı bu çalışmanın gelecekteki olası uygulamaları için ilgi çekici bir yaklaşım olabilir.  
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1. INTRODUCTION 
A carcinoma is any malignant cancer that arises from epithelial cells. Carcinomas invade 
surrounding tissues and organs and may metastasize to other sites such as lymph nodes. 
Although there are several different types of carcinoma, adenocarcinomas (“adeno” meaning 
“pertaining to a gland”) which have glandular cell appearance in terms of histopathology, are 
very common and colorectal cancer (CRC) presents itself nearly 95% of all cases as an 
example to adenocarcinomas. This is because the colon has numerous glands within the 
tissue, which function in mucus secretion into the lumen of the colon and water absorption 
back into the blood, and colorectal adenocarcinomas are malignant epithelial tumours 
originating from glandular epithelium of the colorectal mucosa. The tissue forming these 
glands may undergo a number of changes at the genetic level such as loss of some genes 
including TP53 and move from benign (adenoma stage) to invasive, malignant CRC. [1] CRC 
is the third common form of cancer and the second leading cause of cancer related death in 
the Western World and there is a vast array of risk factors accompanying it such as exposure 
to some viruses, hereditary influences, smoking and diet, physical inactivity and exogenous 
hormones. CRC is seen in both sexes and although surgical intervention cures more than 50% 
of the CRC patients, recurrence is not uncommon that adjuvant (i.e. post-operation) as well as 
neoadjuvant (i.e. pre-operation) therapies are necessary. These include chemotherapeutics 
which in one way or another inhibit the growth of the neoplasm by cell cycle arrest via 
fixation of microtubules, targeting a specific enzyme or growth factor and/or induce 
programmed cell death as in apoptosis.  
HCT 116, a cell line derived from the colon carcinoma of a male human patient is such an 
adenocarcinoma-like cell line. [2] It lacks the hMLH-1 protein, a part of the mismatch repair 
(MMR) system of the cell, and hence the cell is defective in DNA repair necessary for 
genome integrity.  Deficiency in this MMR system is an advantage to tumourigenesis, as it 
happens with accumulation of several genomic alterations such as with enhanced proliferative 
capability and/or compromised programmed cell death and so increased metastatic potential. 
[3] 
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2. BACKGROUND 
Cancer is thought to be caused by the interaction between genetic susceptibility and 
environmental toxins. Since it is not possible to eliminate all the risk factors, therapies have to 
be developed to treat and hopefully cure cancer. There are several different agents for cancer 
therapy which remove blockage to programmed cell death in a transformed cell and restore 
the natural autodestruction machinery by bringing the components such as regulatory Bcl-2 
family proteins into action. [4]  
 
2.1. Cancer 
Cancer is the second most common cause of death in developed countries. About one third of 
the population contracts a cancer related disease during their lifetime and as such cancer 
therapy is a huge market that many investors are interested in. However, it is difficult to 
develop new treatment strategies, especially in the chemotherapy field mainly because cancer 
is a heterogeneous disease and many genetic and epigenetic factors play role in each 
neoplasm in the body of an affected individual. Additionally, chemicals used as 
antiproliferative agents are actually intended to cause cell death and this causes toxicity to the 
healthy tissues.   
Cancer varies vastly depending on the cell type it originates from and the genetic alterations it 
carries. For one cell to acquire the necessary genetic changes within a reasonable time of 
disease progression the diseased tissue needs to be genetically unstable. Six common genetic 
alterations in cell physiology contributing to malignant growth have been suggested. [5]  
• Self-sufficiency in growth signals, and/or 
Insensitivity to anti-growth signals  
• Evasion of cell death - Apoptotic cell death is a suppressed mechanism for 
regulating the number of cells in an organism or cell population to keep healthy. 
The amplitude of proliferative or death signals decides whether or not the cell 
undergoes apoptosis. Tumour cells can acquire resistance to such death signals by 
inactivating pro-apoptotic signalling as in the case of loss of p53 expression, or 
increasing pro-survival Bcl-2 family protein amounts in the cell by 
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overexpression 
• Infinite replicative capacity  
• Sustained angiogenesis  
• Tissue invasion and metastasis   
• Genome instability - In order to gain the traits mentioned above within a 
reasonable time the tumour cells need to have a higher mutation rate than normal 
cells. This is mostly enabled by the inactivation of "genomic caretakers" such as 
p53 which is often found to be not-functional in cancer. 
 
2.1.1. Genes Involved in Cancer 
During carcinogenesis, the cell undergoes many genetic alterations as mentioned above. Some 
of these alterations are related to gain of function via specific point mutations, amplification 
or translocations as in the case of the oncogenes from proto-oncogene precursors. Oncogenes 
are dominant over the normal proto-oncogenes and change in the expression level or protein 
structure of these oncogenes promotes cell division independently of any external stimuli, a 
phenomenon critical for tumourigenesis. [6-7] 
As there are oncogenes promoting the uncontrolled proliferation, there exist also tumour 
suppressor genes which as the name implies counteract and suppress a tumourigenic 
phenotype. [8] TSGs are important in many cellular functions such as apoptosis, signal 
transduction and DNA repair. They can be subdivided into “gatekeepers” which directly 
inhibit cell growth by suppressing proliferation or inducing apoptosis or differentiation, 
“caretakers” which ensure the fidelity of the genome through DNA repair or protection of 
genomic stability and the “landscapers” which are found in the mutated form in the cells 
surrounding the tumour and effect the microenvironment. [9] Rb and p53 are two of the best 
characterized TSGs in human cancers.  
The TP53 gene encodes the p53 transcription factor (TF) sometimes referred to as the 
“guardian of the genome”. In response to stresses such as DNA damage, phosphorylation of 
p53 leads to its stabilization and increased activity as a transcription factor.  
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Fig. 2.a. Guardian of the genome. Cellular stress triggers accumulation of p53 and 
transactivation of target genes that induce cell cycle arrest or apoptosis. Almost 50% of all 
human cancers carry mutations in TP53. [10] 
 
p53 also plays a central role in a cells decision to either induce cell cycle arrest or apoptosis. 
The p53-mediated apoptotic response involves induction of pro-apoptotic Bcl-2 family 
proteins including Bax, Noxa and Puma and repression of anti-apoptotic proteins such as Bcl-
2. These effects together with p53-induced up-regulation of ROS generating enzymes all 
promote mitochondrial membrane permeabilization. [11] In addition, p53 can have 
transcription independent mechanisms of action activating pro-apoptotic proteins in 
mitochondria. [12-13] A role for caspase-2 during DNA damage induced apoptosis upstream 
of mitochondrial events has been established. [14] It promotes the expression of the p53-
induced protein with a death domain (PIDD) which is part of a caspase-2 activating complex, 
the PIDDosome. [15] p53 has also been shown to induce oxidative phosphorylation by 
transactivating the SCO2 gene required for assembly of the cytochrome c oxidase complex, a 
key component of the respiratory chain. Loss of SCO2 by loss of p53, results in defective 
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oxidative phosphorylation, which in turn causes the metabolic shift towards glycolysis for 
ATP production. [16] 
 
Fig. 2.b. p53 signalling pathways for growth arrest and apoptosis. Upon DNA damage, p53-
MDM2 binding is dissociated as a result of p53 phosphorylation by ATM and acetylation by 
p300/pCAF leading to p53 activation. Activated p53 acts as a TF to transactive growth 
regulatory genes such as p21 to induce growth arrest. p53 regulates apoptosis in 
transcriptional-dependent and –independent manners, the former being with induction by 
transactivating the genes in both mitochondrial and death receptor pathways as well as 
transrepressing cellular survival genes such as Bcl-2 and the latter being with binding to 
mitochonia and modulates activity of BH3-containing pro-apoptotic proteins. [17] 
 
Another gene controlled by p53 which has recently been identified, is p53-induced glycolysis 
and apoptosis regulator (TIGAR). TIGAR expression lowers the levels of glycolysis and 
induces up-regulation of the pentose phosphate pathway. This is involved in the synthesis of 
glutathione (GSH), which provides protection against increased ROS levels. Consequently, 
p53-induced expression of TIGAR lowers glycolysis and protects cells from ROS-mediated 
apoptosis. In tumour cells with mutated p53, TIGAR-mediated inhibition of glycolysis does 
not occur and this causes higher glycolytic rate of tumour tissues. [18] As a crucial 
"gatekeeper", p53 is the single most frequently mutated TSG in human cancer, inactivated in 
approximately 50% of all tumours. [19]  
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Fig 2.c. p53 pathway. [20] 
 
2.1.2. Cancer Treatment 
Because of the heterogeneous nature of cancer it is not possible to give a recipe on how to 
treat and hopefully cure a neoplasm. Nevertheless, the first approach, if applicable, is surgical 
excision. Removal of the tumour to any extend possible, minimizes the tumour burden and 
risk of subsequent metastases, as well. The second approach is radiation, where any local 
cancerous cell mass is the target due to its genomic instability and proliferative pressure it is 
under. These two approaches are not effective if the tumour has metastasized beyond lymph 
nodes. At that point, treatment needs to be systemic. Chemotherapeutics and secondary 
adjuvant therapies such as antibody and hormonal can be given systemically to either cure or 
at least slow down the progression of the disease and alleviate the symptoms associated. They 
need to be administered when the number of tumour cells is low enough to permit their 
destruction at doses that can be tolerated by the patient.   
Chemotherapy acts by killing cells that divide rapidly - one of the main properties of cancer 
cells. This also involves harming cells that divide under normal circumstances resulting in 
side-effects. Most chemotherapeutic drugs work by impairing mitosis, effectively targeting 
 7 
 
fast-dividing cells. Malignancies with slower growth rates tend to respond to chemotherapy 
much more modestly. Drugs affect "younger" tumours (i.e., less differentiated) more 
effectively, because mechanisms regulating cell growth are usually still preserved. With 
succeeding generations of tumour cells, differentiation is typically lost, growth becomes less 
regulated, and tumours become less responsive to most chemotherapeutic agents. Near the 
centre of some solid tumours, cell division has effectively ceased, making them insensitive to 
chemotherapy. Another problem with solid tumours is the fact that the chemotherapeutic 
agent often does not reach the core of the tumour. Also over time, cancer cells become more 
resistant to chemotherapy treatments. Recently, regulated pumps on the cell surface of cancer 
cells have been identified which actively move chemotherapeutics from inside the cell to the 
outside. 
The majority of chemotherapeutic drugs can be divided in to alkylating agents, 
antimetabolites, anthracyclines, plant alkaloids, topoisomerase inhibitors, and other 
antitumour agents. All of these drugs affect cell division or DNA synthesis and function in 
some way. 
 
2.1.2.1. Alkylating Agents and Platinum Compounds 
Cancer chemotherapy evolved from the observed effects of sulphur mustard gas on bone 
marrow and lymphoid tissues after exposure during World War I which led to an ambitious 
search for other chemicals with such antitumour activities. The sulphur and nitrogen mustards 
are described to act as alkylating agents. They form strong electrophiles through the formation 
of carbonium ion intermediates. This results in the formation of covalent linkages by 
alkylation of various nucleophilic moieties. The chemotherapeutic and cytotoxic effects are 
not exclusively but directly related to the alkylation of DNA. The nucleophilic groups of 
proteins, RNA and many other molecules can also be the target of such attack. The alkylating 
agents are known to be more cytotoxic to rapidly dividing cells. 
The first platinum antitumour compounds were discovered as a result of studying effects of 
electrical currents on bacterial growth. Growth inhibition was found to occur but was caused 
by a platinum complex of ammonia and chloride produced in the medium at the platinum 
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electrode. Several compounds were found to have antitumour effects and the most active 
platinum compound was found to be Cisplatin. [21] 
Cisplatin, cis-diamminedichloroplatinum(II) (CDDP), has a central role in cancer 
chemotherapy. It is used to cure prostate cancer and also treat ovarian, cervical, head and neck 
and non-small cell lung cancers. The treatment is limited by side effects such as nephro- and 
neurotoxicity, of which neurotoxicity is dose-limiting and can result in peripheral neuropathy 
and hearing loss. [22] Resistance to the treatment is also common as some tumours have 
intrinsic mechanisms against treatment while others develop them during the course of 
treatment. A defective apoptotic program is one of the major contributors to CDDP resistance, 
together with increased drug efflux, decreased drug influx, increased cellular GSH (i.e. 
antioxidant defence of the cell) and metallothionein levels, increased DNA repair and 
oncogene expression. [23] In order to understand the cytotoxicity of CDDP and improve the 
therapeutic response, it is necessary to elucidate the molecular mechanisms of CDDP-induced 
cell death. 
 
 
Fig. 2.d. CDDP resistance mechanisms. GS indicates glutathione and Pol polymerase. [24] 
 
The cellular uptake of CDDP is not fully understood. It has been suggested that drug enters 
the cells partly by passive diffusion through transmembrane channels and partly by facilitated 
diffusion through an unidentified membrane transport system. [25]  
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CDDP is in its typical form a neutral inorganic complex that is activated upon entry into the 
cell, where the low chloride concentration facilitates replacement of the chloro-ligands of 
CDDP with water molecules. The aquated form is highly reactive and the resulting positively 
charged molecule can interact with nucleophilic sites of cellular proteins, membrane 
phospholipids, RNA and DNA. [26] It has been shown that CDDP induces apoptosis also in 
the absence of nucleus [27], indicating that, in addition to its DNA-damaging effects, CDDP 
causes cell death via the other cellular targets. [22] Approximately 1 % of the intracellular 
CDDP reacts with nuclear DNA to yield intra- and inter-strand DNA crosslinks and DNA-
protein crosslinks. The most common adducts are intra-strand cross links between adjacent 
guanines and between neighbouring guanine and adenine, representing 65% and 25%, 
respectively, of the total number of adducts formed. [28]   
 
 
Fig. 2.e. Cisplatin and its DNA adduct. [29] 
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Fig. 2.f. Main adducts formed in the interaction of CDDP with DNA where (a) represents an 
interstrand crosslink, (b) a 1,2-intrastrand crosslink, (c) a 1,3-intrastrand crosslink and (d) 
protein-DNA crosslink. [30] 
 
CDDP adducts are removed from DNA mainly by nucleotide excision repair (NER). The 
MMR system recognizes but does not remove the CDDP adducts since it always replaces the 
incorrect sequence in the daughter strand, leaving the CDDP adduct unrepaired. This initiates 
useless repair cycles which may generate DNA breaks and activate pro-apoptotic signals. [23] 
 
Fig. 2.g. Model for p53 involvement in the mechanism of resistance/sensitivity of tumours to 
CDDP. [31] 
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Binding of DNA-PK to damaged DNA results in phosphorylation and activation of two 
proteins involved in pro-apoptotic signalling, c-Abl and p53. Phosphorylation of p53 results 
in inhibition of its ubiquitination, leading to increased stabilization of the protein. p53 can 
initiate apoptosis as mentioned before by transcriptionally activating pro-apoptotic Bcl-2 
family members such as Bax, Bak, Puma and Noxa, and repressing anti-apoptotic Bcl-2 
proteins (Bcl-2, Bcl-xL) and inhibitors of apoptotic proteins (lAPs). In addition, p53 can 
transactivate other genes that may contribute to apoptosis, including Apaf-1, PTEN, CD95 
and TRAIL receptor 2. [32]  
 
Fig. 2.h. Factors modulating repair of CDDP-induced DNA adducts and regulating replicative 
by-pass. [33] 
 
The HMG proteins are a multifunctional family of small non-histone chromatin-associated 
proteins involved in gene regulation and maintenance of chromatin structure. Binding of 
HMG proteins to CDDP adducts may protect the adducts from recognition by DNA repair 
enzymes, resulting in higher cytotoxicity. Moreover, since these proteins have high affinity 
for CDDP-modified DNA, binding to DNA adducts may keep these proteins away from their 
normal binding sites, thus disturbing a diversity of cellular processes and potentially leading 
to cell death. [30] 
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2.1.3. Outcomes of Cancer Treatment 
As more and more becomes known about the cellular response to damage inflicted by 
chemotherapy more insight is gained on the mode of action of drugs. Chemotherapeutics 
induce several responses affecting proliferation and survival of the cell, ranging from mitotic 
catastrophe, senescence and cell death modalities, i.e. autophagy, necrosis and apoptosis. 
Mitotic catastrophe takes place with DNA damage and deficient cell cycle checkpoints which 
normally keep the cell cycle on hold until the damage is repaired. [34] Non-viable cells with 
smaller nuclei are formed with nuclear envelopes around clusters of missegregated 
chromosomes as a result of aberrant mitosis. [35] Mitotic catastrophe is induced by agents 
interfering with microtubule function as well as by DNA damage. [36-37] Mitotic catastrophe 
is also considered to be a starting point for cell death rather than a type of cell death by its 
own, and execution of cell death takes then place by apoptosis or necrosis. [38-39] 
Senescence is defined as the condition of permanent growth arrest and was first described in 
cultured human fibroblasts that failed to divide after a limited number of cell divisions caused 
by the progressive shortening of telomeric ends by 50-100 base pairs per cell division. [40]  
The senescent cells are metabolically active and show distinctive modifications in their 
morphology such as enlarged and flattened cell shape and increased granularity. In addition to 
the telomere-dependent induction of replicative senescence, DNA damage and other types of 
stress responses also cause a senescence-like phenotype. [41-42] This response involves 
signalling which leads to stabilization of p53 and eventually growth arrest. [43] With tumour 
suppressors such as p53 acting as important regulators of senescence, senescence is 
considered as a tumour suppressor mechanism that cells need to overcome for tumour 
formation. [44] Tumour cells usually circumvent replicative senescence through up-regulation 
of telomerase [45] but can be strained into stress-induced premature senescence in response to 
chemotherapy and radiation. [41-42]   
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Fig. 2.i. The power and the promise of oncogene-induced senescence markers. [46] 
 
Cell death is a fundamental and highly regulated process that is well conserved among diverse 
species. It is a vital process in development and homeostasis of normal organisms. All cells 
are equipped with a genetic program for self-destruction. Defects in cell death are observed in 
numerous physiological disorders including diabetes, neurodegenerative diseases and cancer. 
The naturally occurring turnover of cells in the body is referred to as "programmed cell 
death". The term programmed cell death (PCD) was suggested in 1965 [47] and has been used 
to describe the phenomenon where cells follow a series of genetically controlled steps towards 
their own annihilation. It serves as a major mechanism for removal of redundant and 
potentially dangerous cells, such as virus-infected cells, self-reactive lymphocytes or tumour 
cells. [48] 
Autophagy is an evolutionarily conserved process in which cytoplasmic contents of a cell are 
impounded within double membrane vacuoles called autophagosomes, which subsequently 
fuse with lysosomes where the material inside the autophagosomes are degraded. Autophagy 
functions as a protective response to various cellular stresses such as starvation, changes in 
cell volume, oxidative stress, accumulation of misfolded proteins, hormonal signals and 
irradition, in which the degradation of cytoplasmic material is used as nutrients and source of 
energy as an alternative form of programmed cell death. [49] 
Necrosis has been referred to as the uncontrolled form of cell death which often occurs in 
response to a severe damage or physical insult. It is characterized by swelling of cytoplasm 
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and mitochondria, and loss of membrane integrity resulting in cell rupture and release of 
cellular contents into the surrounding tissue. [10] The resulting inflammatory response is 
allied with systemic toxicity and the activity of immune cells in situ may even support 
malignancy. [50] On the other hand, the stimulation of the immune response could potentiate 
the killing of tumour cells. [51] It is reported that necrosis may also be a regulated process 
triggered by various stimuli such as intracellular Ca2+ overload, excessive production of 
reactive oxygen species (ROS) and cellular energy depletion. [35] There also seems to be an 
overlap between apoptosis and necrosis in response to certain death inducing stimuli 
dependent on the dose.  
The phenomenon of apoptosis was first described as a “shrinkage necrosis” where the 
cells turn into small, round, membrane encapsulated bodies with condensed chromatin 
and undamaged organelles. [52] It was then renamed as "apoptosis" with important roles 
in development, cellular turnover, tissue disorders and atrophy. Morphological changes 
defining apoptosis are condensation of nuclear chromatin, DNA fragmentation via activation 
of endonucleases along with cellular shrinkage and blebbing. Activation of caspase family 
proteases is one hallmark of apoptosis. The resulting apoptotic bodies are quickly 
recognized by their phosphotidylserine (PS) residues they expose on their cell membranes and 
engulfed by cells of the immune system or surrounding tissue so that they do not cause any 
tissue scarring or inflammation. [10] Apoptosis is an active, organized and intrinsic 
occurrence, in contrast to normal necrosis which is a rapid and "aggressive" process 
ensuing in interruption of cellular homeostasis. It occurs in tumours spontaneously as 
well as in response to some anticancer treatments. [53] Studies performed in the nematode 
Caenorhabditis elegans have provided important information on the strict genetic control of 
the apoptosis. [54] Several genes specifically required for induction and execution of 
apoptosis were identified and homologs of many of these genes have been found in mammals. 
These include both oncogenes such as Bcl-2 and tumour suppressor genes such as TP53. [55] 
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Fig. 2.j. Role of apoptosis in disease; it is required for the maintenance of tissue homeostasis. 
[10] 
 
2.1.3.1. Biochemistry of Apoptosis 
The apoptotic process can be divided into three phases:  
1. Initiation phase - Many different intra- and extracellular signals such as signals from cell 
membrane, physical and chemical stresses, and oncogene expression have been shown to 
induce cell death. In this phase, the signals are detected and signalling pathways are induced 
in response to the stimuli. 
2. Effector phase - In this phase the signals are transmitted and if necessary amplified inside 
the cell so that the execution can start.  
3. Execution phase - The activated apoptotic machinery works on different cellular targets to 
cleave DNA and specific cellular proteins. 
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There are two initiator pathways which activate the execution of cell death: the extrinsic 
and the intrinsic pathways. Activation of either of these two pathways results in activation 
of caspases, the main executors of cell death.  
Caspases are a family of cysteine proteinases conserved among a range of species which 
specifically cleave their substrates after aspartic acid residues. The distinctive substrate 
specificity is determined by the four residues amino-terminal to the cleavage site. Caspases 
exist in the cell as inactive proenzymes and need proteolytic cleavage of their prodomain for 
activation. Fully active caspases are tetramers consisting of two large (ca. 20kDa) and two 
small (ca. 10kDa) subunits. They are divided into two subfamilies; (1) proximal or initiator 
caspases, and (2) terminal or effector caspases.  
Initiator caspases include caspase -1, -2, -4, -5, -8, -9, -10 and -12. Once activated, these 
initiator caspases process and activate the effector caspases.  
Effector caspases are mainly activated by another proteinase, in most cases a caspase. 
Effector caspases possess short prodomains and include caspase-3, -6, -7, -11 and -13. Once 
activated, caspases, mainly caspase-3 and -7, cleave their specific substrates contributing to 
the morphological and functional changes associated with apoptosis, such as nuclear 
shrinking is caused by cleavage of nuclear lamin, and loss of cellular shape by cleavage of 
cytoskeletal proteins. Actually more than 100 substrates of the effector caspases have been 
identified so far. The proteins cleaved by caspases fall into four major categories: (1) 
apoptotic proteins such as Bid and Bcl-2 are activated or inactivated by caspase cleavage to 
promote cell death, (2) structural proteins are degraded, contributing to changes in cell shape 
and detachment from the matrix, (3) cellular DNA repair proteins involved in energy 
demanding processes are removed to save ATP for apoptotic mechanisms and (4) cleavage of 
cell cycle proteins is speculated to aid in cell death in response to improper cell cycle 
signalling by oncogenes. [51] 
Due to there potential pro-apoptotic effects, caspases are strictly regulated both at 
transcriptional [56-57], and posttranslational level. Posttranslational modifications such as 
nitrosylation, oxidation, ubiquitination and phosphorylation have been shown to control 
caspase activity. [58]  
The B-celllymphoma-2 (BcI-2) family proteins are regulatory proteins in the initiation of 
caspase activation and apoptosis. These proteins control the intrinsic apoptotic pathway by 
managing the release of caspase activating proteins from mitochondria via establishing 
mitochondrial membrane permeability. [59] In addition to this, Bcl-2 family proteins also 
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localize to other intracellular membranes such as the endoplasmic reticulum (ER) where they 
influence apoptotic signalling. In humans, twenty five members of this family have been 
discovered. The Bcl-2 family proteins can be divided in two groups: anti-apoptotic members, 
such as Bcl-2, Bcl-xL Mcl-1, and pro-apoptotic member, such as Bak, Bax, Bim, Noxa. They 
are related through their conservation of helical sequences called Bcl-2 homology (BH) 
domains and each Bcl-2 family protein contains at least one of these four BH-domains, BH1,-
2,-3, and -4. [60] The anti-apoptotic members display conservation in all four BH domains 
and a C-terminal hydrophobic tail allowing these proteins to be anchored to the membranes of 
mitochondria, ER and nucleus. All pro-apoptotic members lack BH4. [61] They are either 
multidomain proteins, possessing the BH1, -2 and -3 domains and intrinsic death-inducing 
activity as for Bax and Bak [4], or BH3-only proteins (BOPs) having homology only within 
the BH3 domain, also called the "minimal death domain" as for Bid, Bad, Bim. Pro-apoptotic 
family members are normally found in the cytosol or are loosely associated with membranes. 
After a death signal, these proteins translocate to the intracellular membranes, mostly the 
outer mitochondrial membrane, where they either insert into the membrane or interact with 
other proteins. 
Bcl-2 family proteins can interact with each other, forming homodimers, heterodimers and 
oligodimers and can act as agonists or antagonists of their binding partners. Dimerization 
occurs through interaction between the amphiphatic BH3 α-helix of the pro-apoptotic proteins 
and the hydrophobic groove of the anti-apoptotic members, created by the α-helices in the 
BH1, -2 and -3 regions. [61] The ratio between pro- and anti-apoptotic proteins in the cell 
functions as a rheostat that sets the threshold for sensitivity to pro-apoptotic proteins. [62] 
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Fig. 2.k. A model of Bcl-2 family member control over PCD. In response to myriad cell  
death, damage or derangement signals BH3-only family members are activated (i). Activator 
BH3-only proteins interact with multidomain pro-apoptotic Bax and/or Bak inducing their 
oligomerization (ii) and thus resulting in MOMP, release of cyt c, apoptosome formation and 
caspase activion (iii). Bcl-2 and other multidomain anti-apoptotic proteins interrupt the death 
signal by binding and sequestering activator BH3-only proteins and perhaps also Bax/Bak 
(iv). Bcl-2 anti-apoptotic function may be antagonized by the competitive displacement of 
activator BH3-only molecules by sensitizer BH3-only proteins (v). [63] 
 
The pro-apoptotic Bcl-2 proteins can be divided into two classes. The multi-domain protein 
Bax subclass (Bax, Bak and Bok) possess sequence homology for the BH1, -2, and -3 regions. 
[64] These proteins can promote apoptosis via their interaction with the mitochondrial 
membrane leading to release of cytochrome c and activation of caspases. The second subclass 
(Bik, Bim, Blk, Bid, Bad, Puma and Noxa) have strong homology only in the BH3 region. 
[65]  
Bax and Bak have important roles in the intrinsic pathway of cell death at both the 
mitochondria and ER. Bak exists predominantly in mitochondria and ER membranes whereas 
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Bax is found mainly in the cytosol. The gene encoding Bax is a transcriptional target of the 
p53 protein in humans. [66] In response to death stimuli activated Bax and Bak undergo 
homo-oligomerization that results in the permeabilization of the outer mitochondrial 
membrane and the release of cytochrome c from the mitochondria. [67]  
Bad, Bim, and Noxa can induce apoptosis via an interaction with either Bax or Bak and/or 
by generating stable complexes with anti-apoptotic Bcl-2/Bcl-xL. [68-69] The genes 
encoding the BH3-only proteins Puma and Noxa are transcriptionally transactivated by p53. 
[70-71]  
 
 
Fig. 2.l. Several Bcl-2 family proteins with similar structure and anti-apoptotic activity 
have been identified, including Mcl-1, Bcl-xL, and Boo. [59] These Bcl-2 family 
proteins have a COOH-terminal hydrophobic transmembrane domain which directs 
them to the membranes of mitochondria, ER and the nucleus. [72] 
 
Bcl-2 was first identified in the chromosomal breakpoint (t14:18) of chronic lymphocytic 
leukemia (CLL). [73] It was later described as an oncogene which protected against 
apoptosis. [74] Bcl-2 is now known to protect against most forms of apoptotic and 
sometimes necrotic cell death regardless of caspase involvement. [59] Association of Bcl-2 
has been demonstrated in various processes, including regulation of calcium homeostasis [75-
76], modulation of antioxidant pathways [77], promotion of gluthathione sequestration to the 
nucleus [78] and abrogation of cytochrome c release from mitochondria [79-80].  Bcl-2 
resides in the outer mitochondrial membrane, ER and nuclear membranes. [81-82] It can also 
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bind non-homologous proteins such as Raf-l and calcineurin. Bcl-2 mediates translocation of 
Raf-l to the vicinity of the mitochondrial membrane. Once there, Raf-1 phosphorylates Bad, a 
pro-apoptotic BOP, the role of which is to heterodimerize with Bcl-2 and/or Bcl-xL and 
abrogate their anti-apoptotic function. Phosphorylated Bad dissociates from Bcl-2 and Bcl-xL 
and forms a cytosolic complex with a scaffold protein that inhibits interference of Bad with 
anti-apoptotic family members. [83-84] Moreover, by binding to calcineurin, a calcium-
activated serine-threonine phosphatase, Bcl-2 may inhibit dephosphorylation of Bad. [85] 
As Bcl-2 is constitutively membrane bound, Bcl-xL associates with membranes only if 
stimulated. [86] The BH domains of Bcl-2 and Bcl-xL have been shown to form a 
hydrophobic pocket in which Bak and Bax are bound and sequestered. [62] In addition, 
also BOPs including Bim, Bad and Noxa bind to Bcl-2 and Bcl-xL, which indirectly 
inhibits Bak and Bax activation by oligomerization of the pro-apoptotic proteins and/or 
their insertion into the mitochondrial membrane. A model, where anti-apoptotic proteins 
inhibit activation of Bak and Bax by sequestering BOPs, has also been suggested. [69, 87] 
Bcl-xL can bind and sequester the non-Bcl-2 protein Apaf-1 thus inhibiting formation of 
the apoptosome. [88-89] Bcl-xL, together with Bcl-2, has been suggested to prevent 
mitochondrial membrane permeability either by physically or functionally interacting with 
voltage-dependent anion channel (VDAC), by neutralizing adenine nucleotide translocator 
(ANT) channel activity, or a combination of all of these [90] or by inhibition of pro-a pop to 
tic proteins such as Bax and Bak. [91]  
Posttranslational modifications such as phosphorylation and cleavage regulate the activity of 
Bcl-2 and Bcl-xL. Chemotherapeutic agents that cause microtubule disruption have been 
reported to induce phosphorylation of Bcl-2 and Bcl-xL, abrogating their anti-apoptotic 
function. [92-93] It has been suggested that phosphorylation within the loop region of the 
Bcl-2 protein may determine the susceptibility to the cleavage by altering the conformational 
change and making the cleavage site more accessible to proteases. [94] Caspase-dependent 
cleavage of Bcl-2 and Bcl-xL may occur in response to phenomena like Fas ligation, 
etoposide and growth factor withdrawal. Cleavage results in the exposure of the BH3 
domains, converting these anti-apoptotic proteins into promoters of cell death. [95] Cleavage 
of Bcl-2 and Bcl-xL can also be mediated by calpain, a calcium activated protease. [96] 
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Fig. 2.m. Bcl-2 family proteins with similar structure and pro-apoptotic activity. [72] 
 
2.1.3.2. Apoptotic Pathways 
There are two apoptotic pathways which the cell can follow to commit apoptosis according to 
the origin of the death stimulus, extrinsic or intrinsic. These two pathways may overlap or 
take place at the same time, and some machinery they exploit may be common to both. 
 
Fig. 2.n. Apoptotic pathways in overview. [97] 
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The extrinsic, or death receptor-mediated pathway, is triggered by ligand binding to cell 
surface death receptors. [62] The best characterized initiation of this pathway is through 
the tumour necrosis factor receptor (TNFR) family proteins; TNFR1, Fas (CD95 or 
Apo1) and DR4 (TRAIL-R1) along with -5 (TRAIL-R2). They contain structurally 
similar intracellular domains, death domains (DD) which is responsible for signalling 
initiation. [98] Upon ligand binding the receptor subunits trimerize and adaptor proteins 
TRADD (for TNF) and FADD (for FasL and TRAILs) are recruited to the receptor. 
Caspase-8 can cleave Bid to produce truncated Bid (tBid) which triggers the intrinsic 
apoptotic pathway by releasing cytochrome c from the mitochondria [99], activation of 
caspase-9 which cleaves caspase-3, which in turn further activates caspase-8 to amplify 
the signal. [100] Hence, caspase-8 is the key initiator caspase in the extrinsic pathway of 
apoptosis and Bid is a link between the extrinsic and intrinsic apoptotic pathways. 
The intrinsic pathway utilizes organelles to amplify the death signals. [35] Mitochondria 
have a central role in intrinsic pathway of apoptosis. [90] Various signals induced by stress 
stimuli such as cytotoxic drugs, DNA damaging agents, hypoxia, heat shock, growth factor 
withdrawal, irradiation, ROS and death-receptor signalling converge on mitochondria. The 
mitochondrial events observed in response to cellular stress include permeabilization of the 
mitochondrial membranes. There are three models for this phenomenon: 
• Model I  
The permeability transition pore (PTP) is a polyprotein complex formed at the contact sites 
between the outer and the inner mitochondrial membrane. [101]  
• Model II  
Bcl-2 proteins may interact with proteins in the outer mitochondrial membrane, such as 
VDAC, and thereby regulate this channel's activity. [102] Since the pore size of VDAC is 
too small for passage of cytochrome c, it has been suggested that pro-apoptotic Bcl-2 
members induce a conformational change leading to an increase in channel size. Anti-
apoptotic Bcl-2 members would, according to this model, promote closure of the channel and 
thereby inhibit cytochrome c release. [103]  
• Model III  
Insertion of pro-apoptotic Bcl-2 family members into the outer mitochondrial membrane 
may be followed by formation of channels for passage of proteins localized in the 
mitochondrial intermembrane space. It has been shown that Bcl-2 family proteins can insert 
into synthetic lipid bilayers, oligomerize and form channels [104] but it remains unclear 
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whether these channels exist in cells and whether they would be large enough for passage of 
intermembrane proteins. 
Once the mitochondrial membrane has become permeable some proteins are released from 
the mitochondrion during apoptosis. These are: 
• Cytochrome c  
• Smac/DIABLO  
• Omi/HtrA2  
• Endonuclease G  
• Apoptosis inducing factor (AIF)  
 
 
Fig. 2.o.  Death pathways downstream of mitochondrial membrane permeabilization. 
cytochrome c via caspase activation, Smac/Diablo and Omi/HtrA2 via cytochrome c induced 
caspase activation by counteracting inhibitor of apoptosis proteins (IAPs), AIF via caspase 
independent death pathway culminating in DNA fragmentation and stage 1 chromatin 
condensation, EndoG via DNA cleavage and stage 1 chromatin condensation. Ca+2 and ROS 
via severe mitochondrial dysfunction. [105] 
 
2.2. Oxidative Stress 
Oxidative stress arises if there is an imbalance between the oxidative and reductive elements 
within a cell. The imbalance is mainly due to the loss of cell’s ability to readily detoxify the 
reactive intermediates produced during cellular processes or easily repair the resulting damage 
on the components of the cell which is a reducing environment preserved by enzymes. These 
enzymes sustain the reduced status by continuous input of energy. Any disturbance of this 
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redox status results in changes in the cell due to the production of peroxides and free radicals 
(FRs) that damage proteins, lipids and nucleic acids within the cell. 
Oxidative stress may work in two ways. It may stimulate the system for adaptation to the new 
circumstances in the environment the system has to cope with or it may cause damage to the 
components of the system. This solely depends on the concentration of prooxidant substances. 
Usually to overcome increased concentrations of prooxidants within the cells cells’ response 
is to increase the expression of the genes encoding the components of the antioxidant defence 
of the cell. This is only helpful when the concentration of prooxidants is within certain limits.  
 
2.2.1. Free Radicals, Oxygen and Reactive Oxygen Species 
A (free) radical is a molecule with an unpaired (free) electron. The unpaired electron is a 
highly reactive "hot potato" that either "burns" (causes oxidative damage) or is passed from 
molecule to molecule so that the recipient becomes a FR and the donor is neutralized. 
Radicals usually carry zero net charge but can be positively (radical cation) and negatively 
(radical anion), too. The high reactivity of FRs comes from the fact that orbitals around the 
nucleus of an atom are more stable when they are occupied with a pair of electrons and not a 
single electron alone. FR damage can happen on lipids, proteins and nucleic acids in the cell.  
The main site for FR production in the cell is the mitochondrion so most damage due to FRs 
is observed in mitochondrial membranes and mitochondrial DNA. [106] Some 1 to 5% 
fraction of the oxygen used in mitochondria to generate energy via aerobic respiration results 
in the formation of superoxide radicals. 
There is a great range of FRs that can be formed in the human body such as H•, OH•, O2-, 
H2O2 (non radical oxygen derivative which acts as an oxidant in the cell), RO•, RO2•, HO2•. 
The reactivity of any FR varies according to its chemical properties. 
Oxygen is a highly reactive nonmetallic period 2 element that readily forms compounds with 
almost all other elements. At standard temperature and pressure two atoms of the element 
bind to form dioxygen, a colorless, odorless, tasteless diatomic gas with the formula O2. 
Oxygen is the third most abundant element in the universe by mass after hydrogen and helium 
and the most abundant element by mass in the Earth's crust. Diatomic oxygen gas constitutes 
20.9% of the volume of air. It is vital for higher organisms but there is evidence that it can be 
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toxic as it inhibits cellular enzymes. Yet the rates of enzyme inhibition if any are too slow. So 
the damage attributed oxygen is due to the formation of oxygen FRs (OFR). [107] 
Most FRs in biological systems are derivatives of oxygen (Reactive Oxygen Species, ROS) 
but there are also derivatives of nitrogen (Reactive Nitrogen Species, RNS). There are also 
Reactive Oxygen Intermediates, ROI which exist only for a short time so that they are 
relatively more reactive than other ROS. 
 
Oxidant Description 
•O2-, superoxide 
anion 
One-electron reduction state of O2, formed in many autoxidation 
reactions and by the electron transport chain. Rather unreactive but can 
release Fe2+ from iron-sulfur proteins and ferritin. Undergoes 
dismutation to form H2O2 spontaneously or by enzymatic catalysis and 
is a precursor for metal-catalyzed •OH formation. 
H2O2, hydrogen 
peroxide 
Two-electron reduction state, formed by dismutation of •O2- or by direct 
reduction of O2. Lipid soluble and thus able to diffuse across 
membranes. 
•OH, hydroxyl 
radical 
Three-electron reduction state, formed by Fenton reaction and 
decomposition of peroxynitrite. Extremely reactive, will attack most 
cellular components 
ROOH, organic 
hydroperoxide 
Formed by radical reactions with cellular components such as lipids and 
nucleobases. 
RO•, alkoxy and 
ROO•, peroxy 
radicals 
Oxygen centred organic radicals. Lipid forms participate in lipid 
peroxidation reactions. Produced in the presence of oxygen by radical 
addition to double bonds or hydrogen abstraction. 
HOCl, 
hypochlorous acid 
Formed from H2O2 by myeloperoxidase. Lipid soluble and highly 
reactive. Will readily oxidize protein constituents, including thiol 
groups, amino groups and methionine. 
ONOO-, 
peroxynitrite 
Formed in a rapid reaction between •O2- and NO•. Lipid soluble and 
similar in reactivity to hypochlorous acid. Protonation forms 
peroxynitrous acid, which can undergo homolytic cleavage to form 
hydroxyl radical and nitrogen dioxide. 
Table 2.a. Some common oxidants (adapted from [108-109])  
 26 
 
A non-reactive molecule can be made into a FR in two ways: either it accepts an additional 
free electron and becomes a FR or it loses one of its electrons and is left with a single electron 
free to react with other molecules. A process called homolytic fission takes place when a 
covalent bond is broken and the shared electron pair is equally distributed among the parties 
of the covalent bond so that from a single covalently bonded molecule two radicals are 
formed. [110]  
A : B → A• + B • 
An example to homolytic fission is a water molecule ending up as a hydrogen radical (H•) 
and a hydroxyl radical (OH•).  
Another process called heterolytic fission takes place when a covalent bond is broken and the 
shared electron pair stays at one of the parties of the covalent bond so that from a single 
covalently bonded molecule one positively charged and one negatively charged ions are 
formed. 
A : B → A:- + B+ 
An example to heterolytic fission is a water molecule ending up as a hydrogen ion (H+) and a 
hydroxide ion (OH-). 
The main source of FR generation is normal metabolic processes of the cell. Other extrinsic 
factors such as ultraviolet light (UV) also cause FR generation. During the process of 
respiration, cells are continuously subjected to oxidative stress as semi-reduced species of 
oxygen are also produced when molecular oxygen is reduced to water. Such semi-reduced 
species of oxygen (Reactive Oxygen Species, ROS) are highly reactive and initiate a series of 
oxidative reactions also referred to as oxidative stress.  
As mentioned before, FRs are highly reactive towards cellular macromolecules such as lipids, 
proteins, and nucleic acids. They may cause modified enzyme function and increased cellular 
Ca+2 concentration by aggregating and cross linking, fragmenting and breaking down, 
modifying thiol groups of or nitrating phenolic compounds in proteins, decreased membrane 
fluidity by destroying of polyunsaturated fatty acids, forming reactive metabolites, altering 
activity of membrane bound receptor and transporters with lipids,  inhibition of protein 
synthesis, activation of certain genes or translational errors by damaging bases, fragmenting 
or breaking deoxyribose rings in nucleic acids. On the other hand, FRs can also act as second 
messengers in the induction of molecular process. 
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2.2.2. Effects of ROS on Cellular Macromolecules 
Protein oxidation is any covalent modification of a protein induced by ROI or by-products of 
oxidative stress. There is a vast array of agents that lead to protein oxidation. Some are 
chemical reagents such as H2O2, GSH, 1O2; UV light, ozone; lipid peroxides such as HNE, 
MDA; mitochondria via electron transport chain leakage; P-450 enzymes and drugs and their 
metabolites. There are several different types of protein oxidative modifications such as sulfur 
oxidation as in cysteine disulfides; nitrosation, hydroxylation; hydro(pero)xy derivatives of 
aliphatic amino acids; amino acid interconversions such as histidine to asparagines or proline 
to OH-proline; lipid peroxidation adducts as with MDA, HNE; amino acid oxidation adducts 
such as p-hydroxyphenylacetaldehyde; peptide bond cleavages and protein carbonyls with 
side chain aldehydes and ketones. Amino acids have different tendencies to oxidation.  
Cysteine  Disulfides, mixed disulfides (e.g., glutathiolation), HNE-Cys 
Methionine  Methionine sulfoxide 
Tyrosine Dityrosine, nitrotyrosine, chlorotyrosines 
Tryptophan Hydroxy- and nitro-tryptophans, kynurenines  
Phenylalanine Hydroxyphenylalanines  
Valine, Leucine Hydro(pero)xides  
Histidine 2-Oxohistidine, asparagine, aspartate, HNE-His 
Glutamyl Oxalic acid, pyruvic acid 
Proline Hydroxyproline, pyrrolidone, glutamic semialdehyde 
Arginine Glutamic semialdehyde, chloramines 
Lysine MDA-Lys, HNE-Lys 
Table 2.b. The most susceptible amino acids and their main reaction products. [111-112] 
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The biochemical consequences of protein oxidative modification can be severe. It can cause 
loss or gain of enzyme activity, loss of protein function, loss of protease inhibitor activity, 
protein aggregation (e.g., IgG, LDL, prion protein), enhanced susceptibility to proteolysis , 
diminished susceptibility to proteolysis, abnormal cellular uptake (e.g., LDL), modified gene 
transcription (e.g., SoxR, IkB), increased immunogenicity (e.g., ovalbumin; HNE- or 
acrolein-LDL) etc. There are many diseases and conditions in which protein oxidation has 
been implicated such as atherosclerosis (LDL), rheumatoid arthritis (IgG, a-1-proteinase 
inhibitor), neurodegenerative diseases, Alzheimer’s and Parkinson’s disease and cancer. 
Protein oxidation can be overcome by the use of antioxidants, scavengers such as methionine, 
antioxidant enzymes such as catalase and SOD, antioxidant enzyme mimics, chelators, 
depletion of O2 and augmentation of cellular antioxidant systems as with acetylcysteine which 
increases the intracellular GSH. 
There are advantages as well as disadvantages when using proteins as markers of oxidative 
stress. To start with, there is no single universal marker for protein oxidation. The types of 
modification depend highly on the nature of the oxidant. But the products are relatively stable 
to perform assays for the source of oxidant and there are very sensitive assays which can 
detect oxidized products in amounts less than 1 pmols. Different forms of oxidative 
modification have different functional consequences. For instance, methionine is highly 
susceptible but oxidation often does not affect protein function. But although carbonyls are 
often associated with dysfunction but these modifications may require more stringent 
oxidative conditions. Proteins, lipids, and DNA are modified by different oxidants to different 
degrees. DNA has more affinity to be modified in the presence of H2O2 than lipids which are 
far more reactive than proteins. 
There are different methods for the detection of protein oxidation products depending on the 
oxidant and its target. In case of carbonyls, the first set of methods employ 
dinitrophenylhydrazine (DNPH) – coupled assays. These include techniques such as 
spectroscopy, high pressure liquid chromatography (HPLC), Western Blotting (OxyBlot™), 
ELISA and immunohistochemistry. [113-115]  
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Fig. 2.p. Detection of oxidized proteins by use of DNPH. [113] 
 
Carbonyl groups are relatively stable. They are normally present at low levels in most protein 
preparations (~1 nmol/mg protein ~ 0.05 mol/mol ~ 1/3000 amino acids). In vivo this 
background protein carbonyls can be elevated 2 to 8 fold under conditions of oxidative stress. 
They can be induced by almost all types of oxidants such as site-specific metal catalyzed 
oxidation, γ-irradiation, HOCl, ozone or lipid peroxide adducts. If the source of protein 
carbonyls is metal catalyzed oxidation the amino acids of interest are proline (g-
glutamylsemialdehyde), arginine (g-glutamylsemialdehyde), lysine (amino-
adipicsemialdehyde) and threonine (amino-ketobutyrate). 
When detection of protein carbonyls will be done by western blotting there are some point 
which should be kept in mind. Firstly, carbohydrate groups of glycoproteins do not contribute 
to carbonyl levels [116] but free aldehyde groups  from lipid peroxidation adducts (e.g., 
MDA) can react with DNPH. To overcome this phenomenon the adducts need to be stable. 
One other important point is that the western blot assay is only semi-quantitative but it can be 
used on cell and tissue extracts. [111] 
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Fig. 2.r. Carbonylation and derivatization of a protein amino acid side chain. [117] 
 
In case of protein sulfur group oxidations, cysteine and methionine are the most susceptible 
amino acids. This type of oxidation is distinguished from other oxidative protein 
modifications in that the cells have mechanisms to reverse the oxidation such as methonine 
sulfoxide reductase and GSH or thioredoxin redox systems and hence it may serve a 
regulatory function. Reversible oxidation/reduction of methionine may protect proteins from 
more damaging forms of oxidative modification as in carbonyl formation. [118] 
Lipid peroxidation refers to the oxidative degradation of lipids. It is the process whereby FRs 
"steal" electrons from the lipids in cell membranes, resulting in cell damage. This process 
proceeds by a FR chain reaction mechanism. It most often affects polyunsaturated fatty acids, 
because they contain multiple double bonds in between which lie methylene (i.e. -CH2-) 
groups that possess especially reactive hydrogens. As with any radical reaction the reaction 
consists of three major steps: initiation, propagation and termination. 
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Initiation is the step whereby a fatty acid radical is produced. The initiators in living cells are 
most notably reactive oxygen species (ROS), such as OH·, which combines with a hydrogen 
atom to make water and a fatty acid radical. 
The fatty acid radical is not a very stable molecule, so it reacts readily with molecular oxygen, 
thereby creating a peroxyl-fatty acid radical. This too is an unstable species that reacts with 
another free fatty acid producing a different fatty acid radical and a lipid peroxide or a cyclic 
peroxide if it had reacted with itself. This cycle continues as the new fatty acid radical reacts 
in the same way. 
 
Fig. 2.s. Mechanisms of lipid peroxidation. 
 
When a radical reacts it always produces another radical, which is why the process is called a 
"chain reaction mechanism." The radical reaction stops when two radicals react and produce a 
non-radical species. This happens only when the concentration of radical species is high 
enough for there to be a high probability of two radicals actually colliding. Living organisms 
have evolved different molecules that speed up termination by catching FRs and therefore 
protect the cell membrane. One important such antioxidant is vitamin E. Other anti-oxidants 
made within the body include the enzymes superoxide dismutase, catalase, and peroxidase. 
If not terminated fast enough, there will be damage to the cell membrane, which consists 
mainly of lipids. [119]  
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In addition, end products of lipid peroxidation may be mutagenic and carcinogenic. For 
instance, the end product malondialdehyde reacts with deoxyadenosine and deoxyguanosine 
in DNA, forming DNA adducts to them. [120]  
Malondialdehyde is the organic compound with the formula CH2(CHO)2. The structure of this 
species is more complex than this formula suggests. This reactive species occurs naturally and 
is a marker for oxidative stress. This compound is a reactive aldehyde and is one of the many 
reactive electrophile species that cause toxic stress in cells and form covalent protein adducts 
which are referred to as advanced lipoxidation end products (ALE), in analogy to advanced 
glycation end-products (AGE). The production of this aldehyde is used as a biomarker to 
measure the level of oxidative stress in an organism. TBARS Assay is a typical method using 
MDA as a marker of lipid peroxidation. 
 
2.2.3. Antioxidant Defence Mechanism of the Cell 
Cellular response to oxidative stress is a certainty in cells. [121] Various genes and gene 
proteins have been identified which act in the antioxidant defence mechanism of the cell. In 
addition to these, there are also other molecules called antioxidants acting chemically against 
the prooxidants in the cell. Antioxidants are defined as any substance that can delay or 
prevent the oxidation of a substrate when it is present in relatively smaller amounts than the 
oxidants. Antioxidants share the following assets:  
• They have to cleanse the cells from FR species by protein catalysts (enzymes) or direct 
chemical reactions where they act as reactants 
• They have to minimize the extend of FR formation  
• They have to bind metal ions that are essential to convert poorly reactive species such 
as O2- and H2O2 into highly reactive species such as OH• 
• They have to be able to repair the damage on the target  
• or to destroy the damaged target and replace with newly synthesized molecules if 
damage cannot be repaired 
The first line of defence mechanism against FRs in vivo is antioxidant enzymes or compounds 
with low molecular weight. GSH-dependent enzymes, i.e. glutathione peroxidase (GPX), 
glutathione reductase and glutathione transferase, catalase - which breaks down H2O2 to 
oxygen and water - and superoxide dismutase - which converts superoxide to H2O2 - account 
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for antioxidant enzymes. Low molecular weight compounds such as vitamin C, vitamin E, 
and carotenoids taken up with daily diet account for antioxidant molecules. There are also 
intrinsic molecules such as GSH, bilirubin and uric acid which act as antioxidant molecules in 
the human body.  
Antioxidant enzymes provide an important defence against FRs in the human body. 
Glutathione peroxidase, glutathione reductase, catalase, thioredoxin reductase, superoxide 
dismutase, Heme oxygenase and biliverdin reductase, are the most important antioxidant 
enzymes. 
Superoxide dismutase without glutathione peroxidase or catalase (CAT) to remove hydrogen 
peroxide is of little value. To eliminate hydrogen peroxide before a specific process by Fe+2 
ion called Fenton Reaction can create the more reactive hydroxyl radical, cells utilize catalase 
and/or glutathione peroxidase.  
The brain due to the high metabolic rate, high unsaturated fat content of the neurons and the 
fact that neurons are post-mitotic is more susceptible to FR damage than other tissues that its 
glutathione peroxidase activity is seven times more than its catalase activity. [122] Moreover, 
glutathione peroxidase is found throughout the cell as other antioxidant enzymes tend to be 
localized in different compartments in the cell. 
Antioxidants are molecules that can neutralize FRs by accepting or donating an electron to 
overcome the unpaired electron condition. In most cases, the antioxidant molecule neutralizes 
a FR molecule as it becomes the FR itself but the FR it becomes is much less reactive than the 
FR it neutralized. It does so by diluting the unpaired electron in case it is a very large 
molecule or by being readily neutralized by another antioxidant and/or another mechanism for 
terminating its FR condition.  
Molecules with loosely-held hydrogen atoms can use those hydrogen atoms like electrons to 
neutralize FRs. The hydrogen atoms are called reducing equivalents, and the molecules 
having such hydrogen atoms are said to be in a reduced state. 
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Fig. 2.t. N-acetyl-L-cysteine structure. .
N-Acetyl-L-Cysteine (NAC) is the amino acid L-Cysteine with an acetyl (-CO-CH3) group 
attached to its amino (NH2) group. The acetyl group increases the solubility and absorbability 
of the L-Cysteine. Amino acids which contain a sulphur group have antioxidant properties.  
L-cysteine itself is not very water soluble and it is not well absorbed in the gastrointestinal 
tract. Dietary cysteine originates mainly from the breakdown ingested protein and peptides. 
Whey protein is a particularly rich food for cysteine.  
Because cysteine is so unstable, the main extracellular source of intracellular cysteine is the 
dipeptide cystine (two conjugated cysteines). Cystine competes with glutamate for transport 
into cells such that conditions of elevated extracellular glutamate can lead to GSH depletion, 
worsened oxidative stress and cell death. [123] 
  
Fig. 2.u. Cystine to cysteine.  
Oral supplementation of NAC provides an alternative means of extra intracellular GSH via 
elevated intracellular cysteine. NAC is rapidly absorbed after oral administration and reaches 
a maximum plasma level in 2-3 hours, with a half-life of about 6 hours. NAC readily enters 
cells. 
Previous reports show evidence that NAC can rescue neurons from apoptotic death in the 
absence of growth factors by activation of the Ras-Extracellular signal Regulated Kinase 
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(ERK) pathway, an effect due to direct action on transcription factors by the thiol group, 
rather than by anti-oxidant effects. [124] In earlier studies it was shown that NAC has been 
used to regenerate oxidative phosphorylation complexes in mitochondria from age-related 
decline in function by sulphhydryl group action, rather than antioxidant effect [125] and that 
NAC protects against radiation damage by a direct radical scavenger action rather than by 
conversion to GSH [126]. By contrast it was also shown before that NAC added to cell culture 
causes increase in oxidative damage to DNA, an effect that can be inhibited by catalase and 
copper chelation. [127] 
 
Fig. 2.v. L-gamma-glutamyl-L-cysteinylglycine structure. 
L-gamma-glutamyl-L-cysteinylglycine, in short glutathione (GSH) is a tripeptide that 
contains an unusual peptide linkage between the amine group of cysteine and the carboxyl 
group of the glutamate side chains. GSH acts as an antioxidant and protects cells from 
damage by FRs. It is the predominant anti-oxidant in the aqueous cytoplasm of cells. Nearly 
all cells require GSH for viability and function although it is not an essential nutrient as it can 
be synthesized from three amino acids, L-cysteine, L-glutamic acid and glycine. NAC is 
processed in the cell to L-cysteine and used in the de novo synthesis of GSH. The synthesis 
takes place in two adenosine triphosphate-dependent steps: First, gamma-glutamylcysteine is 
synthesized from L-glutamate and cysteine via the enzyme gamma-glutamylcysteine 
synthetase (also called glutamate cysteine ligase, GCL). This reaction is the rate-limiting step 
in GSH synthesis as the availability of cysteine controls the reaction rate while glycine and 
glutamic acid are plentiful in cells. Second, glycine is added to the C-terminal of gamma-
glutamylcysteine via the enzyme glutathione synthetase. 
Previous studies showed that GSH can induce p53-dependent apoptosis in cancer cells.  [128] 
The hydrogen atom in the thiol (i. e. -SH) group of many sulphur-containing antioxidants as 
GSH can act as an electron for neutralizing free-radicals. The thiol groups are kept in a 
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reduced state at a concentration of approximately 5mM in animal cells. In healthy systems, 
more than 90% of the total GSH pool is in the reduced form (GSH) and less than 10% exists 
in the disulfide form (GSSG). An increased GSSG-to-GSH ratio is considered indicative of 
oxidative stress. GSH reduces any disulfide bond formed within cytoplasmic proteins to 
cysteine by acting as an electron donor where GSH is converted to its oxidized form GSH 
disulfide (GSSG). GSH is found almost exclusively in its reduced form since the enzyme 
glutathione reductase, which reverts GSH from its oxidized form, is constitutively active and 
inducible upon oxidative stress. The ratio of reduced GSH to oxidized GSSG within cells is 
can be employed as a measure of cellular toxicity. 
 
Fig. 2.w. Inactivation of CDDP by GSH. (X-SH indicates GSH or cysteinylglycine) [33] 
GSH can scavenge peroxynitrite and hydroxyl radicals as well as convert hydrogen peroxide 
to water. In the process a glutathione radical GS• is formed but it is readily neutralized by 
another GS• to produce GSSG. GSSG can be converted back to GSH by NADPH-dependent 
glutathione reductase. Vitamin C can regenerate a Vitamin E radical and GSH can regenerate 
a Vitamin C radical to its antioxidant Vitamin C condition creating a chain of antioxidant 
molecule dependency. 
The GSH system (GSH, glutathione peroxidase and glutathione reductase) is a key defense 
against hydrogen peroxide and other peroxides. There are four forms of glutathione 
peroxidase (GPx) enzymes: (1) cystolic Glutathione Peroxidase (cGPx, ubiquitously 
distributed), (2) Phospholipid Hydroperoxidase Glutathione Peroxidase (PHGPx, in plasma 
membranes to reduce hydroperoxides of complex lipids), (3) plasma Glutathione Peroxidase 
(pGPx, in blood plasma) and (4) Gastro-Intestinal Glutathione Peroxidase (GIGPx, in the liver 
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and GI tract only). The kidney manufactures most pGPx. Selenium is an essential component 
of GPx, so the relative preservation of enzyme levels during selenium deficiency may provide 
a guide to their relative importance. [129] 
 
Fig. 2.y. GSH/GSSG Redox Pair Anti-Oxidant Defence. 
 
2.2.4. Oxidative Stress and Cellular Signalling 
Usually extracellular environment is more oxidized than intracellular environment causing 
formation of disulfide bridges between cysteine amino acid residues exposed to the exterior so 
that complementary surfaces have the ability to maintain a covalent bond that stabilizes the 
structure. This is important for extracellular proteins constantly exposed to a variety of 
proteases capable of degrading proteins with loose structures easily. On the other hand, inside 
the cell the environment is reduced. Here, cysteine residues are not involved in the formation 
of disulfide bonds, unless intracellular redox balance is disturbed via oxidative stress. The 
formation of disulfide bonds alters both conformation and activity of a number of enzymes, 
especially phosphatases. These enzymes usually control the activity of protein kinases, i. e. 
protein phosphorylases. Inactivation of a specific phosphatase by oxidative stress results in 
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sustained activity of kinases which in a cell means increasing activation of certain 
intracellular signal cascades. Such alterations in the intracellular signal cascades proceeding 
through subsequent phosphorylations of certain kinases that operate in a pathway end in 
phosphorylation of proteins in many cell compartments, such as mitochondria or nucleus. 
This modification of specific regulatory proteins can result in a number of changes, ranging 
from ionic signals to wide alterations in patterns of gene expression resulting in protein 
products such as antioxidant enzyme, growth arrest, DNA repair, mitochondrial electron 
transport, cell adhesion, cytokine, and glucose-regulated proteins. As a consequence, a cell 
may change its rate of proliferation, or die, depending on the signal networks. An intracellular 
oscillation of oxidant levels has been previously reported to be associated with the 
maintenance of the rate of cell proliferation. [130]  
 
Fig. 2.z. Model for dysregulation of ROS and SAPKs in transformed cells setting the cellular 
response to anticancer agents. [131] 
Hydrogen peroxide is one of the best-studied oxidising agents, which is used as endogenous 
messenger within the cell. 
It is still not fully elucidated how changes in the intracellular ROS levels are recognized and 
translated into control of expression of certain genes including antioxidant enzymes, repair 
proteins and transcription factors which are inducible transcriptional activator proteins that 
enable activation of a certain gene as a response to physiological and ROS triggered signals. 
These activator proteins respond to diverse stimuli by binding to specific DNA sequences and 
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either stimulating or inhibiting the transcription of the nearby gene. Oxidative stress response 
is related in the activation of various functionally unrelated genes of signal transduction and 
cell proliferation processes. The mammalian oxidative stress has a protective function. 
Activation of the genes depends not only on intracellular redox status but also on other 
physiological signals, whether extrinsic or intrinsic. In both cases ROS act as intracellular 
signalling, i. e. secondary messenger molecules. Hence, it can be deduced that ROS induced 
gene expression is not only restricted to unfavourable environmental conditions but has a 
broader and elemental role in cellular processes. 
Intracellular ROS levels and the induction of apoptosis are shown to be closely associated 
with each other. ROS usually act as mediator of apoptotic response. First evidence to this is 
that the increased ROS or oxidative damage marker levels are observed in cells committing 
apoptosis. Second evidence shows that antioxidants protect cells from committing apoptosis 
which was induced by different stimuli. It has been shown before that apoptosis proceeds as 
intracellular ROS levels increase or intracellular antioxidant concentrations decrease. If a cell 
commits apoptosis, there are many potential sources of ROS, the most important being the 
mitochondria. With the release of cytochrome c from mitochondria, electron transport chain 
gets blocked and consequently superoxide and other ROIs are generated. 
In this study, the aim was to elucidate further on the mechanisms behind CDDP-induced cell 
death, particularly in terms of increased ROS levels and their possible effect on protein targets 
of CDDP. The proteins under examination were pro-survival proteins of the apoptotic 
machinery, specifically Bcl-2, Mcl-1 and Bcl-xL. An additional parameter, the presence (wt) 
or absence (-/-) of TP53 gene in the HCT 116 human colon carcinoma cell line employed 
throughout the studies, was put into the equation as the protein product of this gene is known 
to be a transcription factor to several other genes including those expressing proteins which 
provide protection against increased ROS levels. 
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3. MATERIALS AND METHODS 
3.1. MATERIALS 
3.1.1. Buffers and Solutions 
The list of buffers and solutions with respective data on them is given in the appendix A. 
3.1.2. Chemicals and Antibodies 
The list of chemicals and antibodies exploited is given in the appendix B. 
3.1.3. Molecular Biology Kits 
The list of molecular biology kits exploited is given in the appendix C. 
3.1.4. Laboratory Equipment 
The list of laboratory equipment exploited is given in the appendix D. 
3.1.5. Other Materials Needed 
The list of other materials needed is given in the appendix E. 
3.2. METHODS 
3.2.1. Cell Culture and Treatments 
HCT 116 wt and p53-/- cell lines were kindly provided by Bert Vogelstein at Johns Hopkins 
Oncology Centre, Baltimore, USA.  
Both cell lines were cultured in modified McCoy’s 5A medium and maintained in a 
humidified incubator steadily at 37˚C and 5% CO2. 
Instructions on basic cell culture techniques, how to employ a hematocytometer for 
determination of cell density and administration of drug and/or supplement are given in 
appendix F. 
3.2.2. Assessment of Cell Viability 
MTT Assay procedure was performed according to manufacturer’s instructions. Detailed 
information is given in appendix F. 
3.2.3. Assessment of Apoptotic Response 
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Flow Cytometric Analyses by Annexin-V Labelling was performed according to 
manufacturer’s instructions. Detailed information is given in appendix F. 
3.2.4. Assessment of ROS Production 
Flow Cytometric Analyses by DCFH-DA Labelling was performed according to 
manufacturer’s instructions. Detailed information is given in appendix F. 
3.2.5. Assessment of Lipid Peroxidation 
TBARS Assay was performed according to the previously optimized procedure. Detailed 
information is given in appendix F.  
3.2.6. Assessment of Protein Carbonylation via OxyBlot™ 
Detailed information on protein isolation, immunoprecipitation, Bradford’s protein content 
assay, SDS-PAGE gel preparation and electrophoresis, Western blotting, OxyBlot™ 
procedure and respective detection techniques are given in appendix F. 
3.2.7. Statistical Analyses 
Data were interpreted as means ± standard deviation (SD). For statistical comparison t-test 
was applied. p-values smaller than 0.05 (*) and 0.01 (**) were considered to be statistically 
significant. 
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4. RESULTS 
 
4.1. Effect of CDDP on Cell Viability  
To investigate the effect of CDDP administration on HCT 116 wt and p53-/- cells in terms of 
cell viability MTT Assay was employed. In MTT Assay 96-well plates were seeded with the 
two cell lines at a density of 2.0x104 cells/well for 24h and 1.2x104 cells for 48h treatments. 
Data obtained from seven different sets were given as average percentage with respect to 
controls ± SD. 
To demonstrate the relation between dose and cell viability different concentrations of CDDP 
(0, 12, 30 and 60µM) were administered to HCT 116 wt and p53-/- cells for a pre-set duration 
of treatment (24 and 48h).  
For 24h treatment cell viability was found to be following a decreasing pattern similar in both 
cell lines with increasing doses of CDDP. Here, for the wt cells the cell viability decreased 
down to 94.4, 80.8 and 72.3% for 12, 30 and 60 µM CDDP, respectively when the untreated 
control was taken as 100%. For p53-/- cells the cell viability decreased down to 95.8, 76.4 and 
55% for 12, 30 and 60 µM CDDP, respectively when the untreated control was taken as 
100%. The p53-/- cells proved to be less proliferative than the wt cells. (Fig. 4.1.a.)  
For 48h treatment cell viability was found to be following a declining pattern in both cell lines 
with increasing doses of CDDP. Here, for the wt cells the cell viability decreased down to 
54.3, 30.51 and 26.96%  for 12, 30 and 60 µM CDDP, respectively when the untreated control 
was taken as 100%. For p53-/- cells the cell viability decreased down to 78.03, 66.84 and 
38.81% for 12, 30 and 60µM CDDP, respectively when the untreated control was taken as 
100%. The wt cells showed intermediately less proliferative than the p53-/- cells.  (Fig. 4.1.b.) 
 43 
 
 
 Fig. 4.1.a. MTT Assay for assessment of cell viability. Both cell lines were seeded in 96-well 
plates at a density of 2.0x104 cells/well and treated 24h with different concentrations of 
CDDP. Data shown are normalized % mean ± %SD from seven different data sets.(*: p < 0.05 
and **: p < 0.01) 
 
 
 Fig. 4.1.b. MTT Assay for assessment of cell viability. Both cell lines were seeded in 96-well 
plates at a density of 1.2x104 cells/well and treated 48h with different concentrations of 
CDDP. Data shown are normalized % mean ± %SD from seven different data sets.(*: p < 0.05 
and **: p < 0.01) 
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To demonstrate the relation between duration of treatment and cell viability pre-set 
concentrations of CDDP (0 and 30µM) were administered to HCT 116 wt and p53-/- cells for 
different durations of treatment (24h and 48h). 
Cell viability was found to be lessening in both cell lines in time. In 24h, for the wt cells the 
cell viability decreased down to 80.8% as for p53-/- cells 76.4% for 30µM CDDP when the 
untreated control was taken as 100%. In 48h, for the wt cells the cell viability decreased down 
to 30.5% as for p53-/- cells 66.8% for 30µM CDDP when the untreated control was taken as 
100%. The wt cells showed a steeper loss of cell viability in 48h than the p53-/- as for 24h the 
decrease in both cell lines was proximate. (Fig. 4.1.c.) 
 
 
Fig. 4.1.c. MTT Assay for assessment of cell viability. Both cell lines were seeded in 96-well 
plates at a density of 2.0x104 cells/well for 24h and 1.2x104 cells/well for 48h and treated with 
different concentrations of CDDP. Data shown are normalized % mean ± %SD from seven 
different data sets.(*: p < 0.05 and **: p < 0.01) 
 
Administration of NAC was performed an hour before the CDDP treatment at a final 
concentration of 0.5mM. CDDP was then added into the same medium either at increasing 
concentrations (0, 12, 30 and 60µM) for pre-set duration of treatment (24h or 48h) or at pre-
set concentrations (0 and 30 µM) for increasing duration of treatment (24h and 48h) to clarify 
the dose- and time-dependencies.  
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For 24h treatment cell viability was found to be restored to a certain extend as responsive to 
NAC pre-treatment in both cell lines. Here, for the wt cells the change in cell viability was 
found to be 2.12, 4.84 and 2.1% for 12, 30 and 60 µM CDDP, respectively when compared to 
CDDP only with the untreated control taken as 100%. For p53-/- cells the change was again 
positive with 2.74, 5.24 and 8.43% for 12, 30 and 60 µM CDDP, respectively when compared 
to CDDP only with the untreated control taken as 100%. The p53-/- cells showed 
susceptibility to loss of cell viability in the presence of NAC as in the absence, too than the wt 
cells and they proved to be slightly more responsive to NAC pre-treatment than the wt cells 
for 24h treatment. (Fig. 4.1.d) 
For 48h treatment cell viability was found to be restored to a certain extend as responsive to 
NAC pre-treatment in both cell lines. Here, for the wt cells the observed change was 14.4, 
17.2, 5.42% for 12, 30 and 60 µM CDDP, respectively when compared to CDDP only with 
the untreated control taken as 100%. For p53-/- cells the incline was observed as 4.82, 13.2, 
4.24% for 12, 30 and 60 µM CDDP, respectively when compared to CDDP only with the 
untreated control taken as 100%. The wt cells proved to be more prone to loss of cell viability 
in the presence of NAC as in the absence, too than the p53-/- cells yet the p53-/- cells proved 
to be slightly more responsive to NAC pre-treatment than the wt cells. (Fig. 4.1.e.)  
 
 
 Fig. 4.1.d. MTT Assay for assessment of cell viability. Both cell lines were seeded in 96-well 
plates at a density of 2.0x104 cells/well and treated 24h with different concentrations of 
CDDP in the presence of 0.5mM NAC. Data shown are mean ± SD from seven different data 
sets.(*: p < 0.05 and **: p < 0.01) 
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Fig. 4.1.e. MTT Assay for assessment of cell viability. Both cell lines were seeded in 96-well 
plates at a density of 1.2x104 cells/well and treated 48h with different concentrations of 
CDDP in the presence of 0.5mM NAC. Data shown are mean ± SD from seven different data 
sets.(*: p < 0.05 and **: p < 0.01) 
 
Cell viability was found to be restored to a certain extend as responsive to NAC pre-treatment 
in both cell lines with time. In 24h, for the wt cells there was increase by 4.84% as for p53-/- 
cells by 5.24% for 30µM CDDP when compared to CDDP only with the untreated control 
taken as 100%. In 48h, for the wt cells there was increase by 17.2% as for p53-/- cells by 
13.2% for 30µM CDDP when compared to CDDP only with the untreated control taken as 
100%.The p53-/- cells proved to be more responsive to NAC pre-treatment for 24h treatment 
with CDDP as it was the wt  responded better to NAC pre-treatment in terms of restoration of 
cell viability for 48h treatment with CDDP. (Fig. 4.1.f.) 
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Fig. 4.1.f. MTT Assay for assessment of cell viability. Both cell lines were seeded in 96-well 
plates at a density of 2.0x104 cells/well for 24h and 1.2x104 cells/well for 48h and treated 
with different concentrations of CDDP in the presence of  0.5mM NAC. Data shown are mean 
± SD from seven different data sets.(*: p < 0.05 and **: p < 0.01) 
 
4.2. Effect of CDDP on Apoptotic Response 
To investigate the effect of CDDP administration on HCT 116 wt and p53-/- cells in terms of 
apoptotic response Flow Cytometric Analyses by Annexin-V Labelling was employed. In 
Flow Cytometric Analyses by Annexin-V Labelling 12-well plates were seeded with the two 
cell lines at a density of 2.5x105 cells/well for 24h and 1.5x105 cells for 48h treatments. Data 
obtained were given as folds normalized according to the controls. 
To demonstrate the relation between dose and apoptotic response different concentrations of 
CDDP (0, 12, 30 and 60µM) were administered to HCT 116 wt and p53-/- cells for a pre-set 
duration of treatment (24 and 48h).  
For 24h treatment apoptotic response was found to be following an escalating pattern similar 
in both cell lines with increasing doses of CDDP. Here, for the wt cells the increase continued 
by 2.86, 3.83 and 4.9 fold for 12, 30 and 60 µM CDDP, respectively when compared to the 
untreated control in a normalized manner. For p53-/- cells sensitivity to apoptosis continued 
by 2.01, 2.43 and 3.58 fold for 12, 30 and 60µM CDDP, respectively when compared to the 
untreated control in a normalized manner. The wt cells showed stronger apoptotic response 
than the p53-/- cells. (Fig. 4.2.a.)  
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For 48h treatment apoptotic response was found to be following an inclining pattern in both 
cell lines with increasing doses of CDDP. Here, for the wt cells the increase continued by 
3.46, 4.71 and 9.58 fold for 12, 30 and 60 µM CDDP, respectively when compared to the 
untreated control in a normalized manner. For p53-/- cells apoptotic response grew more solid 
by 2.33, 2.58 and 4.19 fold for 12, 30 and 60µM CDDP, respectively when compared to the 
untreated control in a normalized manner. The wt cells were proven to be more apoptotic in 
comparison to the p53-/- cells, especially at 60 µM CDDP.  (Fig. 4.2.b.) 
 
 
 Fig.4.2.a. Annexin-V Labelling for apoptotic response in Flow Cytometry. Both cell lines 
were seeded in 12-well plates at a cell density of 2.5x105 cells/well and treated 24h with 
different concentrations of CDDP. Data shown are normalized according to the controls of 
one experiment. 
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Fig. 4.2.b. Annexin-V Labelling for apoptotic response in Flow Cytometry. Both cell lines 
were seeded in 12-well plates at a cell density of 1.5x105 cells/well and treated 48h with 
different concentrations of CDDP. Data shown are normalized according to the controls of 
one experiment 
 
To demonstrate the relation between duration of treatment and apoptotic response pre-set 
concentrations of CDDP (0 and 30µM) were administered to HCT 116 wt and p53-/- cells for 
different durations of treatment (24h and 48h). 
Apoptotic response was found to be intensifying in both cell lines with time. In 24h, for the wt 
cells the strength amplified by 3.83 fold and for p53-/- cells by 2.43 fold for 30µM CDDP 
when compared to CDDP only in a normalized manner according to untreated controls. In 
48h, for the wt cells the apoptotic response was more powerful by 4.71 fold and for p53-/- 
cells by 2.58 fold for 30µM CDDP when compared to CDDP only in a normalized manner 
according to untreated controls. The wt cells showed more resilient apoptotic response in 48h 
than in 24h as the p53-/- cells showed an only slight one in both 24h and 48h and also when 
compared to wt cells. (Fig. 4.2.c.) 
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 Fig. 4.2.c. Annexin-V Labelling for apoptotic response in Flow Cytometry. Both cell lines 
were seeded in 12-well plates at a cell density of 2.5x105 cells/well for 24h and 1.5x105 cells 
for 48h and treated with pre-set concentrations of CDDP (0 and 30µM). Data shown are 
normalized according to the controls of one experiment. 
 
Administration of NAC was performed an hour before the CDDP treatment at a final 
concentration of 0.5mM. CDDP was then added into the same medium either at increasing 
concentrations (0, 12, 30 and 60µM) for pre-set duration of treatment (24h or 48h) or at pre-
set concentrations (0 and 30 µM) for increasing duration of treatment (24h and 48h) to clarify 
the dose- and time-dependencies.  
For 24h treatment apoptotic response was found to be declining as responsive to NAC pre-
treatment in both cell lines. Here, for the wt cells the intensity of the response lessened by 
1.49, 0.23 and 0,91 fold for 12, 30 and 60µM CDDP, respectively when compared to CDDP 
only  in a normalized manner according to untreated controls. For p53-/- cells the apoptotic 
response went down by 0.74, 1 and1.44 fold for 12, 30 and 60µM CDDP, respectively when 
compared to CDDP only in a normalized manner according to untreated controls. The wt cells 
underwent more apoptosis in the presence of NAC as in the absence, too than the p53-/- cells 
yet it is the p53-/- cells which proved to be more responsive to NAC pre-treatment than the wt 
cells. (Fig. 4.2.d.)  
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For 48h treatment apoptotic response was found to be falling as responsive to NAC pre-
treatment in both cell lines. Here, for the wt cells there was a decrease in apoptotic response 
by 1.21, 1.97 and 6.86 fold for 12, 30 and 60µM CDDP, respectively when compared to 
CDDP only in a normalized manner according to untreated controls. For p53-/- cells the drop 
was by 0.8, 0.17 and 1.29 fold for 12, 30 and 60µM CDDP, respectively when compared to 
CDDP only  in a normalized manner according to untreated controls. The p53-/- cells proved 
to be intermediately more prone to apoptosis in the presence of NAC as in the absence, too 
than the wt cells yet it is the wt cells which proved to be more responsive to NAC pre-
treatment than the p53-/- cells. (Fig. 4.2.e.) 
 
 
Fig. 4.2.d. Annexin-V Labelling for apoptotic response in Flow Cytometry. Both cell lines 
were seeded in 12-well plates at a cell density of 2.5x105 cells/well and treated 24h with 
different concentrations of CDDP in the presence of 0.5mM NAC. Data shown are 
normalized according to the controls of one experiment. 
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 Fig. 4.2.e. Annexin-V Labelling for apoptotic response in Flow Cytometry. Both cell lines 
were seeded in 12-well plates at a cell density of 1.5x105 cells/well and treated 48h with 
different concentrations of CDDP in the presence of 0.5mM NAC. Data shown are 
normalized according to the controls of one experiment. 
 
Apoptotic response was found to be diminishing as responsive to NAC pre-treatment in both 
cell lines with time. In 24h, for the wt cells the loss in intensity of the apoptotic response by 
0.23 fold and for p53-/- cells by 1 fold for 30µM CDDP when compared to CDDP only in a 
normalized manner according to untreated controls. In 48h, for the wt cells the drop was by 
1.97 fold and for p53-/- cells by 0.17 fold for 30µM CDDP when compared to CDDP only in 
a normalized manner according to untreated controls. The p53-/- cells proved to be more 
responsive to NAC pre-treatment than the wt cells in 24h yet the late effect of NAC pre-
treatment on wt was observed for 48h. (Fig. 4.2.f.) 
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 Fig. 4.2.f. Annexin-V Labelling for apoptotic response in Flow Cytometry. Both cell lines 
were seeded in 12-well plates at a cell density of 2.5x105 cells/well for 24h and 1.5x105 cells 
for 48h and treated with pre-set concentrations of CDDP (0 and 30µM) in the presence of 
0.5mM NAC. Data shown are normalized according to the controls of one experiment 
 
4.3. Effect of CDDP on ROS Production 
To investigate the effect of CDDP administration on HCT 116 wt and p53-/- cells in terms of 
intracellular ROS levels Flow Cytometric Analyses by DCFH-DA Labelling of ROS was 
employed. In Flow Cytometric Analyses by DCFH-DA Labelling of ROS 12-well plates were 
seeded with the two cell lines at a density of 2.5x105 cells/well for 24h and 1.5x105 cells for 
48h treatments. Data obtained were given as folds normalized according to the controls. 
To demonstrate the relation between dose and intracellular ROS levels different 
concentrations of CDDP (0, 12, 30 and 60µM) were administered to HCT 116 wt and p53-/- 
cells for a pre-set duration of treatment (24 and 48h).  
For 24h treatment intracellular ROS levels were found to be following an increasing pattern in 
both cell lines with increasing doses of CDDP. Here, for the wt cells the intensification in 
ROS production continued by 3.32, 3.97 and 4.53 fold for 12, 30 and 60 µM CDDP, 
respectively when compared to the untreated control in a normalized manner. For p53-/- cells 
the increase in ROS production continued by 3.04 and 3.24 fold for 12 and 30µM CDDP, 
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respectively when compared to the untreated control in a normalized manner, yet there was a 
sudden decrease in ROS levels in this cell line for treatment with 60µM CDDP by 1.2 fold 
compared to the 30µM CDDP treatment. When the datum of the sudden decrease omitted, 
p53-/- cells showed an intermediate dominance in intracellular ROS levels than the wt cells. 
(Fig. 4.3.a.)  
For 48h treatment intracellular ROS levels were found to be following an escalating pattern 
very similar in both cell lines with increasing doses of CDDP. Here, for the wt cells the 
amplification in intracellular ROS levels continued by 4.53, 5.18 and 5.79 fold for 12, 30 and 
60 µM CDDP, respectively when compared to the untreated control  in a normalized manner. 
For p53-/- cells the increase was sustained by 3.67, 5 and 5.75 fold for 12, 30 and 60µM 
CDDP, respectively when compared to the untreated control in a normalized manner. The wt 
cells showed a slightly sharper increase in ROS levels at the 12µM CDDP concentration than 
the p53-/- cells which caught up with the wt at 60 µM CDDP that at the end the p53-/- cells 
were proven to be producing more ROS than the wt cells to a slight extend.  (Fig. 4.3.b.) 
 
 
Fig. 4.3.a. DCFH-DA Labelling of ROS in Flow Cytometry. Both cell lines were seeded in 
12-well plates at a cell density of 2.5x105 cells/well and treated 24h with different 
concentrations of CDDP. Data shown are normalized according to the controls of one 
experiment. 
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Fig. 4.3.b. DCFH-DA Labelling of ROS in Flow Cytometry. Both cell lines were seeded in 
12-well plate at a cell density of 1.5x105 cells/well and treated 48h with different 
concentrations of CDDP. Data shown are normalized according to the controls of one 
experiment. 
 
To demonstrate the relation between duration of treatment and intracellular ROS levels pre-
set concentrations of CDDP (0 and 30µM) were administered to HCT 116 wt and p53-/- cells 
for different durations of treatment (24 and 48h). 
Intracellular ROS levels were found to be rising in both cell lines with time. In 24h, for the wt 
cells the extension of ROS levels was by 3.97 fold and for p53-/- cells by 3.24 fold for 30µM 
CDDP when compared to the untreated control in a normalized manner. In 48h, for the wt 
cells the raise in ROS levels was by 5.18 fold and for p53-/- cells by 5 fold for 30µM CDDP 
when compared to the untreated control in a normalized manner. Although wt cells showed 
more steep increase of ROS levels in 24h than the p53-/- cells, both cell lines revealed 
proximate ROS levels at 48h. (Fig. 4.3.c.) 
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Fig. 4.3.c. DCFH-DA Labelling of ROS in Flow Cytometry. Both cell lines were seeded in 
12-well plates at a cell density of 2.5x105 cells/well for 24h and 1.5x105 cells for 48h and 
treated with pre-set concentrations of CDDP (0 and 30µM). Data shown are normalized 
according to the controls of one experiment 
 
Administration of NAC was performed an hour before the CDDP treatment at a final 
concentration of 0.5mM. CDDP was then added into the same medium either at increasing 
concentrations (0, 12, 30 and 60µM) for pre-set duration of treatment (24h or 48h) or at pre-
set concentrations (0 and 30 µM) for increasing duration of treatment (24h and 48h) to clarify 
the dose- and time-dependencies. 
For 24h treatment intracellular ROS levels were found to be decreasing as responsive to NAC 
pre-treatment in both cell lines. Here, for the wt cells there was a decline in ROS levels by 
1.32, 1.93 and 1.69 fold for 12, 30 and 60µM CDDP, respectively when compared to CDDP 
only in a normalized manner according to untreated controls. For p53-/- cells the fall was  
0.06, 0.12 and 0.58 fold for 12, 30 and 60µM CDDP, respectively when compared to CDDP 
only  in a normalized manner according to untreated controls. Here again the sudden lessening 
in ROS levels in p53-/- cell line for treatment with 60µM CDDP by 1.2 fold compared to the 
30µM CDDP treatment should be kept in mind yet the datum was omitted when comparison 
between the two cell lines was performed. Besides, the drop-off due to NAC pre-treatment 
was still observed. The p53-/- cells showed more ROS production in the presence of NAC as 
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in the absence, too than the wt cells but the wt cells proved to be more responsive to NAC 
pre-treatment than the p53-/- cells as well. (Fig. 4.3.d.)   
For 48h treatment intracellular ROS levels were found to be lessening as responsive to NAC 
pre-treatment in both cell lines. Here, for the wt cells the ROS levels diminished by 0.5, 0.08 
and 0.59 fold for 12, 30 and 60µM CDDP, respectively when compared to CDDP only in a 
normalized manner according to untreated controls. For p53-/- cells the drop was by 0.74, 1.7 
and 0.5 fold for 12, 30 and 60µM CDDP, respectively when compared to CDDP only  in a 
normalized manner according to untreated controls. The p53-/- cells showed slightly sharper 
increase in intracellular ROS levels in the presence of NAC as in the absence, too than the wt 
cells but the wt cells proved to be more responsive to NAC pre-treatment than the p53-/- cells. 
(Fig. 4.3.e.)   
 
  
Fig. 4.3.d. DCFH-DA Labelling of ROS in Flow Cytometry. Both cell lines were seeded in 
12-well plates at a cell density of 2.5x105 cells/well and treated 24h with different 
concentrations of CDDP in the presence or absence of 0.5mM NAC. Data shown are 
normalized according to the controls of one experiment.  
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Fig. 4.3.e. DCFH-DA Labelling of ROS in Flow Cytometry. Both cell lines were seeded in 
12-well plates at a cell density of 1.5x105 cells/well and treated 48h with different 
concentrations of CDDP in the presence or absence of 0.5mM NAC. Data shown are 
normalized according to the controls of one experiment.  
 
Intracellular ROS levels were found to be decreasing as responsive to NAC pre-treatment in 
both cell lines with time. In 24h, for the wt cells the intracellular ROS levels dropped by 1.93 
fold and for p53-/- cells by 0.12 fold for 30µM CDDP when compared to CDDP only in a 
normalized manner according to untreated controls. In 48h, for the wt cells the decline in ROS 
levels was 0.08 fold and for p53-/- cells by 1.7 fold for 30µM CDDP when compared to 
CDDP only in a normalized manner according to untreated controls. The wt cells proved to be 
more responsive to NAC pre-treatment than the p53-/- cells in 24h yet the late effect of NAC 
pre-treatment on p53-/- was observed for 48h. (Fig. 4.3.f.)   
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 Fig. 4.3.f. DCFH-DA Labelling of ROS in Flow Cytometry. Both cell lines were seeded in 
12-well plates at a cell density of 2.5x105 cells/well for 24h and 1.5x105 cells for 48h and 
treated with pre-set concentrations of CDDP (0 and 30µM) in the presence or absence of 
0.5mM NAC. Data shown are normalized according to the controls of one experiment. 
 
4.4. Effect of CDDP on Lipid Peroxidation 
To investigate the effect of CDDP administration on HCT 116 wt and p53-/- cells  in terms of 
intracellular lipid peroxidation levels TBARS Assay was employed. In TBARS Assay 12-well 
plates were seeded with the two cell lines at a density of 2.5x105 cells/well for 24h and 
1.5x105 cells for 48h treatments. Data obtained from three different sets were given as 
average absorbance ± SD.  
To demonstrate the relation between dose and intracellular lipid peroxidation levels different 
concentrations of CDDP (0, 12, 30 and 60µM) were administered to HCT 116 wt and p53-/- 
cells for a pre-set duration of treatment (24 and 48h).  
For 24h treatment intracellular lipid peroxidation levels were found to be following an 
increasing pattern very similar in both cell lines with increasing doses of CDDP. Here, for the 
wt cells the amplification in intracellular lipid peroxidation levels continued given as average 
absorbances from 0.64 in untreated control to 0.7, 0.74 and 0.99 for 12, 30 and 60 µM CDDP, 
respectively. For p53-/- cells the magnification in intracellular lipid peroxidation levels 
persisted given as average absorbances from 0.31 in untreated control to 0.33, 0.48 and 0.71 
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for 12, 30 and 60µM CDDP, respectively. The wt cells showed more lipid peroxidation in 
untreated control which can be considered as a background level that was significantly 
smaller for the p53-/- cell line. The increase from 12 to 30µM CDDP was sharper in p53-/- 
than wt yet this was evened out at 60µM CDDP so that overall change in lipid peroxidation 
levels was intermediately higher in p53-/- cells in comparison with wt cells.  (Fig. 4.4.a.)  
For 48h treatment intracellular lipid peroxidation levels were found to be following an 
escalating pattern in both cell lines with increasing doses of CDDP. Here, for the wt cells the 
increase continued given as average absorbances from 0.47 in untreated control to 0.56, 0.66 
and 0.72 for 12, 30 and 60 µM CDDP, respectively. For p53-/- cells the rise in intracellular 
lipid peroxidation levels persisted given as average absorbances from 0.5 in untreated control 
to 0.56 and 0.77 for 30 and 60µM CDDP, respectively whereas for 12µM CDDP there was 
almost no increase and the average absorbances remained proximate. (Fig 4.4.b.)  
 
 
 Fig. 4.4.a. TBARS Assay for assessment of ROSlipid peroxidation. Both cell lines were 
seeded in 12-well plate at a cell density of 2.5x105 cells/well and treated 24h with different 
concentrations of CDDP. Data shown are mean ±SD from three different data sets.(*: p < 0.05 
and **: p < 0.01)  
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 Fig. 4.4.b. TBARS Assay for assessment of ROSlipid peroxidation. Both cell lines were 
seeded in 12-well plate at a cell density of 1.5x105 cells/well and treated 48h with different 
concentrations of CDDP. Data shown are the mean ±SD from three different data sets.(*: p < 
0.05 and **: p < 0.01) 
 
To demonstrate the relation between duration of treatment and intracellular lipid peroxidation 
levels pre-set concentrations of CDDP (0 and 30µM) were administered to HCT 116 wt and 
p53-/- cells for different durations of treatment (0’, 15’, 30’, 1h, 2h, 4h and 8h as well as 24 
and 48h). 
Intracellular lipid peroxidation levels were found to be following a certain pattern in both cell 
lines within short intervals of time. When treated with 30µM CDDP, for the wt cells the 
change in time given as average absorbances was from 0.03 in t=0 to 0.44 in t=30min, 0.18 in 
t=1h, 0.11 in t=2h, 0.41 in t=4h and 0.15 in t=8h and for p53-/- cells from 0.03 in t=0 to 0.62 
in t=15min, 0.54 in t=30min, 0.36 in t=1h, 0.2 in t=2h, 0.33 in t=4h and 0.3 in t=8h. There 
was almost no change in wt cells at the end of 15min after CDDP administration, other than 
that both cell lines seemed to experience a sudden increase in lipid peroxidation levels shortly 
after CDDP administration which was compensated more and more in time having a 
minimum point at 2h, yet this trend only continued up until a certain duration of treatment, 
specifically at around 4th hour when lipid peroxidation levels had a peak that again was pulled 
down at 8h. (Fig. 4.4.c.) 
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Intracellular lipid peroxidation levels were found to be increasing in both cell lines with time. 
In 24h, for the wt cells the intensification in intracellular lipid peroxidation levels given as 
average absorbances was from 0.64 in untreated control to 0.74 and for p53-/- cells from 0.31 
in untreated control to 0.48 for 30µM CDDP. In 48h, for the wt cells the increase in lipid 
peroxidation levels given as average absorbances was from 0.47 in untreated control to 0.66 
and for p53-/- cells from 0.5 in untreated control to 0.56 for 30µM CDDP. Although wt cells 
showed sharper rise of lipid peroxidation levels in 24h than the p53-/- cells, the slope slowed 
down in 48h so that the outcomes were closer. (Fig. 4.4.d.)  
 
 Fig. 4.4.c. TBARS Assay for assessment of lipid peroxidation. Both cell lines were seeded in 
12-well plate at a cell density of 2.0x105 cells/well and treated with pre-set concentrations of 
CDDP (0 and 30 µM) for different durations of treatment (0, 15’, 30’, 1h, 2h, 4h and 8h). 
Data shown are mean ± SD from three different data sets. (*: p < 0.05 and **: p < 0.01) 
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 Fig. 4.4.d. TBARS Assay for assessment of lipid peroxidation. Both cell lines were seeded in 
12-well plates at a cell density of 2.5x105 cells/well for 24h and 1.5x105 cells for 48h and 
treated with pre-set concentrations of CDDP (0 and 30µM). Data shown are mean ± SD from 
three different data sets. (*: p < 0.05 and **: p < 0.01) 
 
Administration of NAC was performed an hour before the CDDP treatment at a final 
concentration of 0.5mM. CDDP was then added into the same medium either at increasing 
concentrations (0, 12, 30 and 60µM) for pre-set duration of treatment (24h or 48h) or at pre-
set concentrations (0 and 30 µM) for increasing duration of treatment (24h and 48h) to clarify 
the dose- and time-dependencies.  
For 24h treatment intracellular lipid peroxidation levels were found to be declining as 
responsive to NAC pre-treatment in both cell lines. Here, for the wt cells the decrease given 
as difference in average absorbances was 0.13 in untreated control, 0.11 and 0.041 for 12 and 
60µM CDDP, respectively. There was however an increase in average absorbance (0.045) for 
30µM CDDP. For p53-/- cells the decrease given as difference in average absorbances was 
0.034 in untreated control, 0.018, 0.99 and 0.001 for 12, 30 and 60µM CDDP, respectively. 
The wt cells showed slightly sharper increase in the presence of NAC as in the absence, too 
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and they proved generally to be more responsive to NAC pre-treatment than p53-/- cells in 
24h. (Fig. 4.4.e)  
For 48h treatment intracellular lipid peroxidation levels were found to be lessening as 
responsive to NAC pre-treatment in both cell lines. Here, for the wt cells the decrease given 
as difference in average absorbances was 0.04 in untreated control and 0.055 for 30µM 
CDDP. There was however an increase in average absorbance (0.258) for 60 and no change 
for 12 µM CDDP. For p53-/- cells the decrease given as difference in average absorbances 
was 0.087 in untreated control, 0.082, 0.65 and 0.244 for 12, 30 and 60µM CDDP, 
respectively. The wt cells showed slightly more significant amplification in lipid peroxidation 
levels in the presence of NAC as in the absence, too yet it is the p53-/- cells which proved to 
be more responsive to NAC pre-treatment than wt cells in 48h. (Fig. 4.4.f.)  
 
 
Fig. 4.4.e TBARS Assay for assessment of lipid peroxidation. Both cell lines were seeded in 
12-well plate at a cell density of 2.5x105 cells/well and treated 24h with different 
concentrations of CDDP in the presence or absence of 0.5mM  NAC. Data shown are mean ± 
SD from three different data sets.(*: p < 0.05 and **: p < 0.01) 
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Fig. 4.4.f. TBARS Assay for assessment of lipid peroxidation. Both cell lines were seeded in 
12-well plate at a cell density of 1.5x105 cells/well and treated 48h with different 
concentrations of CDDP in the presence or absence of 0.5mM NAC. Data shown are mean ± 
SD from three different data sets.(*: p < 0.05 and **: p < 0.01) 
 
Intracellular lipid peroxidation levels were found to be falling as responsive to NAC pre-
treatment in both cell lines with time. In 24h, for the wt cells the decrease given as difference 
in average absorbances was 0.13 in untreated control as for p53-/- cells 0.034 in untreated 
control and 0.99 for 30µM CDDP. There was however a rise in average absorbance (0.045) 
for 30µM CDDP. In 48h, for the wt cells the decrease given as difference in average 
absorbances was 0.039 in untreated control and 0.055 for 30µM CDDP as for p53-/- cells 
0.087 in untreated control and 0.065 for 30µM CDDP. The p53-/- cells proved to be more 
responsive than wt cells in both 24h and 48h treatments.  (Fig. 4.4.g.)  
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Fig. 4.4.g. TBARS Assay for assessment of lipid peroxidation. Both cell lines were seeded in 
12-well plate at a cell density of 2.5x105 cells/well for 24h and 1.5x105 cells for 48h and 
treated with pre-set concentrations of CDDP (0 and 30µM) in the presence or absence of 
0.5mM NAC. Data shown are mean ± SD from three different data sets. (*: p < 0.05 and **: p 
< 0.01) 
 
 
Results in Overview 
Comparison of the results has been performed according to the slopes of trendlines for each 
set of data specific for one cell type and absence or presence of NAC pre-treatment at either 
various doses of CDDP. The sharper slope being A and that from the other cell line being B, 
from the direct proportion for A corresponding to 100%, B corresponds to x% and (100-x)% 
is the difference between the intensities in their response to treatment whether reaction to 
CDDP, reaction to CDDP + NAC or response strength to NAC pre-treatment. Significance 
levels have been established for this obtained difference:  
• > 10% slight difference 
• >25% intermediate difference, and 
• <25% significant difference in this concept. 
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time 24h 48h 
 CDDP 
CDDP 
+NAC 
response 
to NAC 
CDDP 
CDDP 
+NAC 
response 
to NAC 
MTT p *** p *** p * w ** w ** p * 
Annexin-V w *** w *** p *** w *** p ** w ***
DCFH-DA p ** p *** w *** p * p ** w * 
TBARS p ** w * w ** p 2 w *** p * 
 
Table 4. Summary of the outcomes of the experiments regarding cell type, NAC pre-treatment 
and duration of treatment with various concentrations of CDDP. * indicates slight (up to 
10%), ** indicates intermediate (up to 25%) and *** indicates significant (more than 25%) 
difference and “w” is short for wt and “p” for p53-/- cell type. 
 
4.5. Effect of CDDP on Protein Carbonylation 
For obtaining protein isolates four 100mm dishes were seeded with HCT 116 wt cells at a 
density of 4.0x106 cells/dish and the dishes were kept in the incubator until attachment of 
cells. Upon removal of the initial medium, CDDP was administered at increasing 
concentrations (0, 20, 30 and 90µM) for pre-set duration of treatment (6h and16h) to clarify 
the dose- and time-dependencies of protein carbonylation.  
Total protein isolates were harvested after 6h and 16h of CDDP administration and used as 
samples in the OxyBlot™ procedure.  
These protein isolates revealed carbonylation signals increasing in intensity (i.e. darker bands) 
as with increasing doses of CDDP as well as increasing duration of treatment. (Fig. 4.5.a. and 
Fig. 4.5.b.) 
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lane 1 2 3 4 
CDDP 
in µM 
0 20 30 90 
 
Fig. 4.5.a. OxyBlot™ picture of samples harvested at 6h after administration of CDDP 
 
 
 
    
lane 1 2 3 4 
CDDP 
in µM 
0 20 30 90 
 
Fig. 4.5.b. OxyBlot™ picture of samples harvested at 16h after administration of CDDP 
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OxyBlot™ procedure was also applied to Bcl-2, Bcl-xL, and Mcl-1 protein samples purified 
by immunoprecipitation from total protein isolates of cell cultures treated with 0 or 30µM of 
CDDP in the absence and presence of NAC pre-treatment for 24h. (Fig. 4.5.c, Fig. 4.5.d. and 
Fig. 4.5.d, respectively) 
 
 
Fig. 4.5.c. OxyBlot™ picture of purified Bcl-2 samples from cell cultures harvested 24h after 
administration of CDDP 
 
 
 
Fig. 4.5.d. OxyBlot™ picture of purified Bcl-xL samples from cell cultures harvested 24h 
after administration of CDDP 
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Fig. 4.5.e. OxyBlot™ picture of purified Mcl-1 samples from cell cultures harvested 24h after 
administration of CDDP 
 
4.6. Effect of CDDP on Cell Morphology 
HCT 116 wt and p53-/- cells were treated with various concentrations of CDDP in the 
presence or absence of NAC. Pictures of each culture were taken after 24h with the light 
microscope at a magnification of 40X. 
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Table 4.6. Pictures of wt and p53-/- cells taken under light microscope 40X after 24h 
treatment with various concentrations of CDDP 
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5. DISCUSSION 
Results in the first two sections regarding the cell viability and apoptotic response to CDDP 
treatment indicated that CDDP decreased the cell viability and increased apoptotic cell death 
and these effects are directly proportional to concentration and duration of treatment.  
Here, for determination of the effect of treatment on the cell viability MTT Assay, a standard 
colorimetric assay for measuring the activity of enzymes in mitochondria that reduce MTT to 
formazan, giving a purple color as a measure of mitochondrial activity and also cytotoxicity 
caused by mitochondrial dysfunction, was employed. One disadvantage of this assay has been 
reported as it may give false positives with reactive oxygen metabolites. It was previously 
used in other studies as an assay for determining the enzymatic activity in mitochondria only 
without deducing assumptions about changes in cell viability.  [132] Yet, the objective of the 
assay in this study was assessment of cell viability and the obtained data indicated that cell 
viability tended to lessen with increasing doses of CDDP and with time, an effect that was 
reversed to some extend by the NAC pre-treatment and this proving that some fraction of loss 
of cell viability is ROS-dependent. 
For 24h treatment cell viability was found to be following a decreasing pattern similar in both 
cell lines with increasing doses of CDDP. The p53-/- cells proved to be less proliferative than 
the wt cells by ca. 39% indicating the positive role of p53 on the mechanisms of cell survival 
and also of the intracellular redox equilibrium. (Fig. 4.1.a.) Cell viability was found to be 
restored to a certain extend as responsive to NAC pre-treatment in both cell lines. The p53-/- 
cells showed steeper decline in cell viability in the presence of NAC as in the absence than the 
wt cells pointing out to the importance of p53 as a guardian of the genome and hence cell 
proliferation. [10] They also proved to be more responsive to CDDP administration in the 
presence of NAC pre-treatment than the wt cells by ca. 32% confirming the prior connections 
of cell viability and protective role of p53. [9] (Fig. 4.1.d) Overall for 24h p53-/- cells were 
ca. 10% more responsive to NAC pre-treatment than the wt cells.  
For 48h treatment cell viability was found to be following a decreasing pattern in both cell 
lines with increasing doses of CDDP. The wt cells lost their viability more by ca. 11% than 
the p53-/- cells representative of the fact that the unrepairable damage exerted by ROS given 
enough time can end up with loss of viability, a phenomenon augmented by the p53 related 
induction of cell death machinery. [10] (Fig. 4.1.b.) With NAC pre-treatment cell viability 
was found to be restored to a certain extend in both cell lines. The wt cells proved to be 
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relatively more proliferative in the presence of NAC as in the absence by ca. 15% than the 
p53-/- cells this being a sign of p53-related cell death machinery working properly when 
damage is extensive. [12] Here, Yet the p53-/- cells proved to be ca. 4% more responsive to 
NAC pre-treatment than the wt cells - a value which could be neglected yet pointing out 
towards an affirmation of the same behaviour for 24h treatments. (Fig. 4.1.e.)  
Cell viability was found to be decreasing in both cell lines in time. The wt cells proved to be 
less viable in 48h than the p53-/- as for 24h the diminishing in cell viability in both cell lines 
was proximate. (Fig. 4.1.c.) Cell viability was found to be restored to a certain extend as 
responsive to NAC pre-treatment in both cell lines with time. The p53-/- cells were more 
responsive to NAC pre-treatment for 24h treatment with CDDP as it was the wt cells more 
responsive to NAC pre-treatment for 48h treatment with CDDP. (Fig. 4.1.f.) 
To sum up, the p53-/- cells were more sensitive than the wt cells in 24h in terms of loss of cell 
viability but as duration of treatment was longer wt cells lost viability more than p53-/- 
regardless of NAC pre-treatment. This proves the p53 protein being an activator of 
mechanisms to repair damage done especially on the DNA, that its absence results in loss of 
viability even in shorter terms of time, but also being a promoter of cell death machinery 
when the damage is beyond repair as with longer exposures to CDDP. [14]  
In this study, for determining the apoptotic cell death Flow Cytometric Analyses by Annexin-
V Staining, a technique based on counting, examining, and separating of cells suspended in a 
stream of fluid regarding their affinity to fluorescently labelled Annexin A5 probe which 
binds to the negatively charged phospholipids (phosphatidylserine) exposed on the cell 
surface of apoptotic cells, was employed. Data showed that apoptotic response tends to 
increase with increasing doses of CDDP and time, an effect that was reversed by the NAC 
pre-treatment to some extend.  
For 24h treatment apoptotic response was found to be following an increasing pattern similar 
in both cell lines with increasing doses of CDDP. The wt cells showed stronger apoptotic 
response by ca. 33% than the p53-/- cells certainly due to the role of p53 in induction of 
apoptosis upon the protein’s stabilization via phosphorylation in stress conditions. [15] (Fig. 
4.2.a.) For 24h treatment apoptotic response was found to be repressed as responsive to NAC 
pre-treatment in both cell lines. The wt cells showed more apoptosis in the presence of NAC 
as in the absence than the p53-/- cells by ca. 65% again signifying the importance of p53 in 
regulation of apoptosis [17] yet it is the p53-/- cells which proved to be more responsive to 
NAC pre-treatment by ca. 44% than the wt cells as they lack the p53 protein. (Fig. 4.2.d.)  
 74 
 
For 48h treatment apoptotic response was found to be following an increasing pattern in both 
cell lines with increasing doses of CDDP. The wt cells underwent more apoptosis by ca. 64% 
than the p53-/- cells, especially at 60 µM CDDP where the damage is broader with 48h in 
comparison to 24h and thus the p53-related portion of the apoptotic response becomes 
relatively more dominant. (Fig. 4.2.b.) For 48h treatment apoptotic response was found to be 
restrained as responsive to NAC pre-treatment in both cell lines. The p53-/- cells showed 
sharper promotion of apoptotic response in the presence of NAC as in the absence than the wt 
cells by ca. 22% presumably indicative of p53-independent induction of apoptosis due to 
stress such as lysosome-related activation of cathepsins  or down-regulation of TIGAR due to 
loss of p53 [18] yet it is the wt cells which proved to be more responsive to NAC pre-
treatment by ca. 47% than the p53-/- cells indicative of the weight of p53 on apoptotic 
machinery. [12-13] (Fig. 4.2.e.)  
Apoptotic response was found to be increasing in both cell lines with time. The wt cells 
showed sharper amplification in apoptotic response in 48h than in 24h as the p53-/- cells 
showed slight increase in both 24h and 48h and also when compared to wt cells. (Fig. 4.2.c.) 
Apoptotic response was found to be declining as responsive to NAC pre-treatment in both cell 
lines with time. The p53-/- cells proved to be more responsive to NAC pre-treatment than the 
wt cells in 24h yet the late effect of NAC pre-treatment on wt was observed for 48h. (Fig. 
4.2.f.) 
In short, the wt cells showed stronger reaction than the p53-/- cells in both 24 and 48h 
treatments in the absence of NAC but when the cells were treated with CDDP in combination 
with the antioxidant for 24h the wt and for 48h the p53-/- cells underwent more apoptosis. So 
the increased ROS levels do induce apoptosis significantly in both durations of treatment in 
the presence of p53 and absence of NAC but it is the p53 molecule which is central for the 
apoptotic signalling in shorter treatment when the ROS levels drop. [16, 18]  
Results in next two sections regarding the ROS and lipid peroxidation levels revealed that 
CDDP indeed amplifies the intracellular ROS levels and this effect is directly proportional to 
concentration and duration of treatment. Here, the two methods utilized revealed different 
patterns for CDDP administration in the absence or presence of NAC pre-treatment where 
p53-/- cells are more prone to amplification in intracellular ROS levels than the wt cells and 
they also show inclined lipid peroxidation levels in the absence of NAC pre-treatment as it is 
the wt cells which have higher lipid peroxidation levels in the presence of NAC pre-treatment 
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regardless of duration of treatment. This suggests that the p53 protein causes a metabolic shift 
due to loss of TIGAR and SCO2 resulting in high intracellular ROS.  
For the assessment of changes in the intracellular ROS levels Flow Cytometric Analyses by 
DCFH-DA Labelling of ROS, a technique based on counting, examining, and separating of 
cells suspended in a stream of fluid regarding their luminescence which results from the 
intracellular ROS converting the 2’,7’-dichlorofluorescin diacetate (DCFH-DA) probe to the 
highly fluorescent compound 2’,7’-dichlorofluorescein (DCF) which then via the 
deacetylation by esterases and subsequent oxidation by ROS in the cell turns to non-
fluorescent 2’,7’-dichlorofluorescin, was employed. Data showed that intracellular ROS 
levels tended to increase with increasing doses of CDDP and time, an effect that was reversed 
by the NAC pre-treatment.  
For 24h treatment intracellular ROS levels were found to be following an increasing pattern in 
both cell lines with increasing doses of CDDP. The p53-/- cells showed more ROS by ca. 
17% than the wt cells demonstrating the direct proportion of p53 with metabolism related 
genes such as SCO2 and TIGAR which when down-regulated contribute to increased rates of 
glycolysis that in turn causes increased ROS levels and/or decreased rates of pentose 
phosphate pathway (PPP) that is very important in the cellular GSH synthesis. [16, 18] The 
unexpected datum at 60µM CDDP administered to p53-/- cells of this experimental setup was 
omitted when calculating the percentages for comparison of the behaviour of the two cell 
lines. The decrease in intracellular ROS levels indicates most certainly an experimental error 
and the fact that there is only one set of experiments in ROS level investigation makes it 
impossible to formulate a better judgement. (Fig. 4.3.a.) For 24h treatment intracellular ROS 
levels were found to be decreasing as responsive to NAC pre-treatment in both cell lines. 
Here again the sudden drop-off in ROS levels in p53-/- cell line for treatment with 60µM 
CDDP by 1.2 fold compared to the 30µM CDDP treatment should be kept in mind yet the 
decrease due to NAC pre-treatment was still observed. The p53-/- cells showed more ROS in 
the presence of NAC as in the absence by ca. 59% signifying the regulatory duty of p53 on 
metabolic characteristics of the cancer cell. [16, 18] than the wt cells but the wt cells proved 
to be more responsive to NAC pre-treatment by ca. 41% than the p53-/- cells. (Fig. 4.3.d.)   
For 48h treatment intracellular ROS levels were found to be following an increasing pattern 
very similar in both cell lines with increasing doses of CDDP The wt cells showed a slightly 
stronger enhancement in ROS levels at the 12µM CDDP concentration than the p53-/- cells 
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which caught up with the wt at 60 µM CDDP that at the end the p53-/- cells showed only 
slightly sharper increase by ca. 6% than wt cells, a value which could be neglected.  (Fig. 
4.3.b.) For 48h treatment intracellular ROS levels were found to be lessening as responsive to 
NAC pre-treatment in both cell lines. The p53-/- cells showed slightly steeper rise in ROS 
levels in the presence of NAC as in the absence, too by ca. 16% than the wt cells but again the 
wt cells proved to be more responsive to NAC pre-treatment by ca. 9% than the p53-/- cells 
again a value which could be neglected yet maybe due to mechanisms involving the p53 and 
its regulatory role as a transcription factor. (Fig. 4.3.e.)   
Intracellular ROS levels were found to be increasing in both cell lines with time. Although wt 
cells showed sharper increase of ROS levels in 24h than the p53-/- cells, both cell lines 
revealed proximate ROS levels at 48h. (Fig. 4.3.c.) Intracellular ROS levels were found to be 
diminishing as responsive to NAC pre-treatment in both cell lines with time. The wt cells 
proved to be more responsive to NAC pre-treatment than the p53-/- cells in 24h yet the late 
effect of NAC pre-treatment on p53-/- was observed for 48h. (Fig. 4.3.f.)   
Likewise, for assessment of intracellular lipid peroxidation levels Thiobarbituric Acid 
Reactive Substances (TBARS) Assay, a method based on screening and monitoring of lipid 
hydroperoxides and aldehydes, such as malondialdehyde (MDA), in the cell culture media 
and cell lysate as indicators of oxidative stress, was used. Here, MDA combines with 
thiobarbituric  acid (TBA) to form a fluorescent adduct, that is measured spectroscopically 
and TBARS are expressed as MDA equivalents. This assay although considered as 
significantly error prone gives valuable information about the effect of increased ROS levels 
within the cell on lipids, one of the main macromolecules. Data showed that intracellular lipid 
peroxidation levels tended to increase with increasing doses of CDDP and time, an effect that 
was reversed to some extend by the NAC pre-treatment.  
For 24h treatment intracellular lipid peroxidation levels were found to be following an 
increasing pattern very similar in both cell lines with increasing doses of CDDP although 
starting from the control samples the two cell lines showed a certain, consistent difference in 
absorbance readings throughout the experimental setup. The wt cells showed higher lipid 
peroxidation levels in untreated control which can be considered as a background or 
experimental noise that was significantly smaller for the p53-/- cell line. The rise in 
intracellular lipid peroxidation levels from 12 to 30µM CDDP was sharper in p53-/- than wt 
yet this was evened out at 60µM CDDP so that overall change in lipid peroxidation levels was 
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intermediately higher in p53-/- cells by ca. 17% in comparison with wt cells suggesting p53 to 
act as a transcription factor to some antioxidant enzymes yet not fully uncovered. [11]  (Fig. 
4.4.a.) For 24h treatment intracellular lipid peroxidation levels were found to be decreasing as 
responsive to NAC pre-treatment in both cell lines. There was however an increase in average 
absorbance (0.045) for 30µM CDDP which can only be considered as an experimental error 
bearing in mind that the whole experimental setup was reasonably consistent in data and 
expected outcomes throughout. The wt cells proved to have slightly higher lipid peroxidation 
levels in the presence of NAC by ca. 4% - a value which could be neglected yet they proved 
generally to be more responsive to NAC pre-treatment by ca. 20% than p53-/- cells in 24h. 
(Fig. 4.4.e)  
For 48h treatment intracellular lipid peroxidation levels were found to be following an 
increasing pattern in both cell lines with increasing doses of CDDP. The amplification from 
30 to 60µM CDDP was sharper in p53-/- than wt and the p53-/- cells showed higher lipid 
peroxidation levels by ca. 14%. (Fig 4.4.b.) For 48h treatment intracellular lipid peroxidation 
levels were found to be lessening as responsive to NAC pre-treatment in both cell lines. There 
was however an enhancement in average absorbance (0.258) for 60µM and no change for 
12µM CDDP. As the latter can be ignored, the former indicating the increase designates an 
experimental error. The wt cells showed sharper increase in the presence of NAC by ca. 77% 
yet it is the p53-/- cells which proved to be more responsive to NAC pre-treatment by ca. 4% - 
a value which could be neglected than wt cells in 48h if relevant. (Fig. 4.4.f.)  
Intracellular lipid peroxidation levels were found to be following a certain pattern in both cell 
lines within short intervals of time. There was almost no change in wt cells at the end of 
15min after CDDP administration, other than that both cell lines seemed to experience a 
sudden increase in lipid peroxidation levels shortly after CDDP administration which was 
compensated more and more in time having a minimum point at 2h, yet this trend only 
continued up until a certain duration of treatment, specifically at around 4th hour when lipid 
peroxidation levels had a peak that again was pulled down at 8h. (Fig. 4.4.c.) This pattern is 
pointing towards to a certain cascade of intracellular events regarding the antioxidant defence 
mechanism of the cell. Intracellular lipid peroxidation levels were found to be increasing in 
both cell lines with time. Although wt cells showed sharper rise of lipid peroxidation levels in 
24h than the p53-/- cells, the slope slowed down in 48h so that the outcomes were closer. 
(Fig. 4.4.d.) Intracellular lipid peroxidation levels were found to be diminishing as responsive 
to NAC pre-treatment in both cell lines with time. There was however an amplification in 
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average absorbance (0.045) for 30µM CDDP. The p53-/- cells proved to be more responsive 
to NAC pre-treatment than wt cells in both 24h and 48h treatments. (Fig. 4.4.g.)   
From results obtained in the section regarding protein oxidation it can be deduced that p53 is 
an effective protector against protein carbonylation due to oxidants in the cell. [9] It does not 
only keep the genome but also the proteome of the cell intact whether directly or indirectly. 
Absence of p53 protein makes the cell more prone to non-functional proteins; this may affect 
the apoptotic response in a positive way if it happens in pro-survival proteins, and in a 
negative way if in anti-survival proteins. Data obtained in this work only reveal that pro-
survival proteins are modified and hence might have lost function and thus be contributing to 
the apoptotic response. Yet again the apoptotic machinery is very complex and further studies 
are obligatory to reveal to which extend non-functional proteins enhance the escape from 
programmed cell death. 
For assessment of the extend of carbonylation as an indicator of oxidative modification on 
proteins OxyBlot™, a protocol for immunoblot detection of carbonyl groups (aldehydes and 
ketones) introduced into proteins at lysine, arginine, proline or threonine residues in a site-
specific manner by oxidative reactions with strong oxidants, was employed.  
In a previous study performed in the laboratory of Maria C. Shoshan at Cancer Centrum of 
Karolinska Institute, Sweden carbonylation signals were shown to be intensifying with 
increasing doses of CDDP and time for total protein isolates of wt cells. (Fig. 4.5.a. and Fig. 
4.5.b.) This was confirmative of the relation between CDDP and intracellular ROS levels 
increasing with increasing doses of CDDP and duration of treatment along with the damaging 
effects of ROS on cellular macromolecules, in this case proteins.  
To determine the extend of carbonylation specifically of pro-survival proteins, Bcl-2, Bcl-xL 
and Mcl-1 OxyBlot™ procedure was applied to purified samples from total protein isolates by 
immunoprecipitation, a technique of precipitating a protein antigen out of solution using an 
antibody that specifically binds to that particular protein to isolate and concentrate a particular 
protein from a sample containing many thousands of different proteins by coupling the protein 
and the antibody to a solid substrate, was used. The amount of purified proteins in each 
experiment was evidently very small that detectable amounts unquestionably account for 
carbonylation in those protein samples.  
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Coupling the two procedures (IP and OxyBlot™) has been quite tricky but that it actually 
worked was proven by the results as well as the markers and underivatized/negative controls 
run occasionally along with the derivatized samples. Each time negative controls (samples 
which have not undergone derivatization process) were run in the same or separate gels and 
never gave any signal signifying the coherence of the procedure.  
All three blots for Bcl-2 (Fig. 4.5.c), Bcl-xL (Fig. 4.5.d) and Mcl-1 (Fig. 4.5.e) showed 
detectable carbonylation signals for samples obtained from total protein isolates of p53-/- cell 
cultures treated with 30µM CDDP in the absence of NAC whereas there was no signal in the 
wt samples treated with 30µM CDDP in the absence of NAC and all other samples whether 
controls or CDDP along with NAC even with longer exposure times (up to 2h). This ensures 
the protective role of p53 in case of an oxidative insult on the cell. [11, 16, 18] 
In Fig. 4.5.c. showing the OxyBlot™ of Bcl-2 IP the lanes adjacent to the well holding the IP 
from the p53-/- cell cultures treated with 30µM CDDP in the absence of NAC reveal bands 
but the reason of these false positives is a simple spillage which took place when samples 
were loaded onto the gel.  
Effect of CDDP administration on cell morphologies of the two cell lines in the absence and 
presence of NAC has also been investigated for a pre-set duration of treatment (24h)with 
increasing doses of CDDP. As can be seen on Table 4.6. increasing doses of CDDP has 
overwhelming effects on cells which can be reversed by the NAC pre-treatment to a certain 
extend. Here, wt cells seem to be more responsive to NAC pre-treatment when it comes to 
morphological changes but as the data from the here performed assays indicate morphological 
changes certainly do not represent all that can be encountered inside the cell upon an induced 
disturbance, such as in this case, oxidative stress.  
One point worth mentioning is that the highly transformed cells such as the p53-/- cell line 
employed in this work show a certain resistance to apoptosis especially when the intracellular 
ROS levels decrease. This phenomenon, called the threshold concept, regarding cells’ 
proliferative vs. apoptotic behaviour is shown in figures below. 
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Fig. 5.a. and 5.b. On the left, the graph represents the hypothetical response of normal cells to 
ROS. Under normal conditions cell growth rate varies between A and B, between B and C the 
destructive capacity of ROS is balanced by the protective effects of the cellular antioxidants, 
and beyond a threshold C malignant transformation may occur (E) or cell death is observed 
(D). On the right the graph represents the hypothetical response of transformed cells to ROS. 
At lower ROS levels cell growth might be stimulated followed by an adaptive production of 
antioxidants between a and b which may contribute to resistance of tumour cells to 
subsequent treatments, between b and c destructive activity of ROS is compensated by the 
antioxidants and at a threshold point c where ROS levels are further increased or antioxidants 
reduced the antioxidant mediated self defence becomes exhausted leading to cell death. [133]  
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6. CONCLUSION and FUTURE DIRECTIONS 
Data obtained in this study confirmed the direct proportion between the dose and/or duration 
of treatment with the initial hypothesis of this work – i.e. a direct proportion between 
intracellular ROS levels and dose and/or time of CDDP administered which can be reversed 
by NAC pre-treatment to some extend. Schematic representation is given below. 
 
 CDDP CDDP + NAC response to NAC 
Cell Viability 
 
Apoptotic 
Response 
 
 
ROS Production 
 
 
Lipid 
Peroxidation 
 
 
Table 6. Schematic representation of the data obtained from various assays performed in this 
study, all generalized according to the intensity of reaction to increasing doses of treatment in 
the absence (red) and presence (green) of antioxidant pre-treatment and the difference they 
caused (blue). 
dose
dose
dose
dose
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In light of all the results from the experiments of this study, the concept of sensitization seems 
to be relevant. As known, in preventive medicine ROS have long been associated with 
neoplastic transformation and antioxidants which scavenge FRs have been favoured as 
prophylactic agents protecting from ROS-induced carcinogenesis. But in clinical practice the 
generation of ROS is regarded as a useful process common to all non-surgical anticancer 
therapies. So presence of antioxidants in neoplastic tissue can decrease the efficacy of 
treatment regarding the fraction of cell death dependent on ROS generation for its action and 
hence favouring tumour cell growth and development of multidrug resistance, the latter being 
a serious problem in treating cancer, by DNA strand breaks, chromosomal abnormalities, 
oxidative base modifications and cellular transformation aiding oncogenic activation and 
promotion of growth factors and cytokines by ROS acting as secondary messengers.  [133] So 
cancer cells can be sensitized to treatments such as CDDP administration which causes 
increased intracellular ROS levels and this being a certain fraction of its efficacy by not using 
antioxidants alongside the treatment if not even increase intracellular ROS levels more by use 
of oxidants or inhibitors of antioxidants. If normal cells suffer from severe damage due to 
increased systemic ROS, antioxidants can only be used to reduce side effects allowing higher 
doses of chemotherapeutic in the prospect to obtain more antiproliferative effect due to other 
modes of action of the drug than increased ROS levels. The whole thing can be visualized as a 
balance and the determination of an optimum treatment with respect to the system’s capability 
to deal with increased ROS levels in both healthy and cancerous tissues is of critical 
importance. One other important point is with techniques which have difficulty in effectively 
delivering therapy to the tumour may induce not only tumour growth but also the potential 
resistance of the tumour to subsequent treatments. Local or targeted drug delivery techniques 
would here be of great benefit. Overproduction of ROS may not always initiate the apoptotic 
response to an expected extend as with the p53-/- cells and unlike low ROS levels that induce 
expression of certain antioxidant enzymes such as SOD in the cell may in turn exhaust the 
protective effectiveness of antioxidants resulting in cell death. This is only favourable if the 
cell that dies is a tumour cell and with a normal cell this means severe side effects of the drug. 
CDDP is known to have serious side effects such as nephrotoxicity and hearing loss. 
This study showed that CDDP treatment increases intracellular ROS levels which contribute 
to apoptotic cell death in response to treatment. The mechanisms behind contain the 
transcription factor/effector p53 and carbonylation of pro-survival Bcl-2 family proteins. In 
case for p53 cells which carry constitutively active TP53 can be used throughout the same 
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experimental setup. Data obtained when compared to the results presented in this work would 
further enlighten the involvement of p53 to the modes of action of this drug. Also, use of a 
positive control and/or inhibitor of antioxidants would enable better interpretation of the 
outcomes of this study. For carbonylation of proteins, the first thing which needs to be done is 
to prove that carbonylation on these proteins indeed cause loss of function. For this, the 
primary step is to predict sites for carbonylation on individual proteins with respect to their 
biochemistry, i.e. amino acid sequence and structure in space.  Experimentally this can be 
achieved by on-blot tryptic digestion followed by matrix-assisted laser desorption/ionization 
mass spectrometry (MALDI MS). Data obtained from MALDI MS can be used for protein 
identification via database search and differences can be interpreted as modifications.  In this 
work, immunoprecipitation was used to isolate a certain protein from a total protein mixture 
the technique can be applied to the latter to achieve less diverse sample. Although 
carbonylation is an irreversible modification getting rid of the sepharose beads after 
immunoprecipitation is difficult and interferes with the later OxyBlot™ procedure. At that 
point, a more efficient and less damaging method needs to be established. Candidates for this 
are salting out to interfere with the solubility and heat treatment to break the covalent bonds 
holding the sepharose bead antibody and protein together. 
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 APPENDIX A: Buffers and Solutions 
A.1. Modified McCoy’s 5A Medium 
solvent McCoy’s 5A Medium 
ingredient final concentration 
L-glutamine 2mM 
Penicillin/Streptomycin 
(P/S)Solution (100U/l) 
1U/l≡1%(v/v) 
Fetal Bovine Serum (FBS) 10%(v/v) 
storage at 4˚C until use 
 
A.2. 10X Phosphate Buffered Saline (PBS) 
solvent ddH20 
ingredient final concentration 
NaCl 1.3688M 
KCl 30.18mM 
Na2HPO4.12H2O 64.97mM 
KH2PO4 15.06mM 
final pH adjusted to 7.4 
storage at room temperature 
 
A.3. 1X PBS 
Dilution with ddH20 in the ratio 9:1, ddH20:10X PBS 
A.4. Freezing Mixture (FM) for Cell Stocks 
solvent FBS 
ingredient final concentration 
DMSO 10%(v/v) 
storage at -20˚C until use 
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A.5. 1000X N- Acetyl-L-Cystein (NAC) Solution 
solvent ddH2O 
ingredient final concentration 
NAC 0.5M 
storage at 4˚C until use 
 
A.6. MTT Solution 
solvent PBS 
ingredient final concentration 
MTT Labelling Reagent 5mg/ml 
storage at 4˚C for 4 weeks in dark 
 
A.7. Annexin-V Incubation Buffer 
solvent ddH2O 
ingredient final concentration 
Hepes 10mM 
NaCl 140mM 
CaCl2 2.5mM 
storage at 4˚C until use 
 
A.8. Dichlorofluorescein diacetate (DCFH-DA) Stock Solution 
solvent DMSO 
ingredient final concentration 
DCFH-DA 20.6mM 
storage at 4˚C until use 
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A.9. DCFH-DA Incubation Solution 
solvent PBS 
ingredient final concentration 
DCFH-DA 5µM 
storage in dark; use immediately 
 
A.10. Thiobarbituric Acid (TBA) Solution 
solvent DMSO 
ingredient final concentration 
DCFH-DA 67%(w/v) 
storage at room temperature 
 
Subsequent dilution with ddH2O in the ratio 9:1, ddH20:67%(w/v) TBA yielding the 
6.7%(w/v) TBA Solution 
A.11. Trichloroacetic Acid (TCA) Solution 
solvent ddH2O 
ingredient final concentration 
TCA 10%(w/v) 
storage at room temperature 
 
A.12. Thiobarbituric Acid Reactive Substances (TBARS) Assay Standards 
solvent EtOH 
ingredient final concentration 
1,1,3,3-
Tetramethoxypropane 
0.4167%(v/v) 
storage at room temperature 
 
Subsequent dilution with ddH2O in the ratio 49:1, ddH2O:0.4167%(v/v) 1,1,3,3-
Tetramethoxypropane yielding the 500uM stock. 
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tube number 
final concentration 
in µM 
ddH2O 
in µl 
1,1,3,3-
Tetramethoxypropane 
in µl 
1 0 500 0 
2 0.625 500 500 from tube 3 
3 1.25 500 500 from tube 4 
4 2.5 500 500 from tube 5 
5 5 500 500 from tube 6 
6 10 800 200 from tube 7 
7 50 500 500 from tube 8 
8 100 800 
200 om 500µM 
stock 
 
A.13. 10%  NP-40  
Dilution with ddH20 in the ratio 9:1, ddH20:100% NP-40 
A.14. Cell Lysis Buffer (CLB) 
solvent ddH2O 
ingredient final concentration 
NaCl 150mM 
NP-40 1% 
Tris-HCl 50mM 
final pH adjusted to 8 
storage at -20˚C until use 
additions prior to use final concentration 
PMSF 0.1mM 
protease cocktail inhibitor 10%(v/v) 
either 2-Mercaptoethanol 1.5%(v/v) 
or Dithiothreitol 50mM 
 
A.15. Bradford Reagent for Protein Content Assay 
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Dilution with ddH20 in the ratio 4:1, ddH20:Bradford Stock Solution 
A.16. Bovine Serum Albumin (BSA) Stock Solution 
solvent ddH2O 
ingredient final concentration 
BSA 1mg/ml 
storage at -20˚C until use 
 
Subsequent dilutions with ddH20 in the ratios 1:1, 3:1, 7:1,  etc. ddH20:BSA Stock Solution 
A.17. 1X DNPH Solution 
Dilution with ddH20 in the ratio 9:1, ddH20:10X DNPH Solution 
A.18. 1X Derivatization Control (DC) Solution 
Dilution with ddH20 in the ratio 9:1, ddH20:10X DC Solution 
A.19. 1X Gel Loading Buffer for OxyBlot™ 
solvent ddH2O 
ingredient final concentration 
Tris-HCl at pH 6.8 62.5mM 
Glycerol 10%(v/v) 
2-Mercaptoethanol 0.17875M 
SDS 2%(w/v) 
Bromophenol Blue 0.002%(v/v) 
storage at -20˚C until use 
 
A.19. 4X Tris-Cl Buffer for Separating Gel Solution 
solvent ddH2O 
ingredient final concentration 
Tris 1.5M 
SDS 0.4%(w/v) 
final pH adjusted to 8.8 
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storage at 4˚C 
 
A.20. 15% Separating Gel Solution 
solvent ddH2O 
ingredient final concenntration 
4X Tris-Cl Buffer at pH 8.8 25%(v/v) 
30% Acrylamide / 0.8% 
Bisacrylamide Solution 
50%(v/v) 
storage at 4˚C until use 
additions prior to use volume 
TEMED 0.067%(v/v) 
10%(w/v) APS 0.33%(v/v) 
 
A.21. 4X Tris-Cl Buffer for Stacking Gel Solution 
solvent ddH2O 
ingredient final concentration 
Tris 0.5M 
SDS 0.4%(w/v) 
final pH adjusted to 6.8 
storage at 4˚C until use 
 
A.22. Stacking Gel Solution 
solvent ddH2O 
ingredient volume 
4X Tris-Cl Buffer at pH 6.8 25% 
30%Acrylamide/8%Bisacrylamide 
Solution 
13.05%(v/v) 
storage at 4˚C until use 
additions prior to use volume 
TEMED 0.1%(v/v) 
10%(w/v)APS 0.5%(v/v) 
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A.23. 10X Running Buffer (RB) 
solvent ddH20 
ingredient final concentration 
Tris base 0.25M 
Glycine 1.92M 
SDS 1%(w/v) 
final pH adjusted to 8.5 
storage at room temperature until use 
 
A.24. 1X RB 
Dilution with ddH20 in the ratio 9:1, ddH20:10X RB 
A.25. 10X Transfer Buffer (TB) 
solvent ddH20 
ingredient final concentration 
Tris base 0.125M 
Glycine 0.96M 
final pH adjusted to 8.3 
storage at room temperature until use 
 
A.26. 1X TB 
Dilution with ddH20 in the ratio 9:1, ddH20:10X TB 
additions prior to use final concentration 
MetOH 20%(v/v) 
 
A.27. 1X PBS-T 
Dilution with ddH20 in the ratio 9:1, ddH20:10X PBS 
additions prior to use final concentration 
Tween®20 0.05% 
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A.28. Blocking/Dilution Buffer for OxyBlot™ 
solvent 1X PBS-T 
ingredient final concentration 
BSA 1%(w/v) 
storage at 4˚C until use 
 
A.29. 1˚ Antibody (Ab) Solution for OxyBlot™ 
Dilution with Blocking/Dilution Buffer for OxyBlot™ in the ratio 149:1, Blocking/Dilution 
Buffer for OxyBlot™:1˚ Ab 
A.30. 2˚ Ab Solution for OxyBlot™ 
Dilution with Blocking/Dilution Buffer for OxyBlot™ in the ratio 299:1, Blocking/Dilution 
Buffer for OxyBlot™:2˚ Ab 
A.31. Chemiluminescent Reagent 
Mix Reagent A and Reagent B in equal amounts to end up with an adequate volume covering 
the blot(s) 
A.32. Developer Solution 
Dilution with ddH2O in the ratio 4:1, ddH2O:Developer Stock Solution 
A.33. Fixer Solution 
Dilution with ddH2O in the ratio 4:1, ddH2O:Fixer Stock Solution 
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APPENDIX B: Chemicals and Antibodies 
Name Supplier Catalog Number 
1,1,1-Tris(hydroxymethyl)-methanamide Fluka, Switzerland 93349 
1,1,3,3-Tetramethoxypropane   
1X Trypsin-EDTA Biological Industries, Israel 03-050-1 
2-Mercaptoethanol Sigma, Germany M370-1 
Acrylamide/Bisacrylamide Sigma, Germany A3699 
Ammonium persulfate Sigma, Germany A3678 
Annexin-V-Fluorescein Alexis Biochemicals, USA 
ALX-209-250-
T100 
Anti-Bcl-2 Antibody Cell Signal Tech, USA 2872 
Anti-Bcl-xL Antibody Cell Signal Tech, USA 2762 
Anti-Mcl-1 Antibody Cell Signal Tech, USA 4572 
Bovine Serum Albumin   
Bradford Stock Solution   
Bromophenol Blue   
cis-diamminedichloridoplatinum(II)   
Dichlorofluorescein diacetate   
Dimethyl sulfoxide Sigma, Germany D2650 
Dithiothreitol   
Ethanol  Riedel-de-Haén, Germany 32221 
Fetal Bovine Serum Sigma, Germany F2442 
Glycerol Riedel-de-Haén, Germany 15523 
Glycine Amnesa, USA 0167 
Hydrochloric Acid Merck, Germany 100314 
Isopropanol Riedel-de-Haén, Germany 24137 
Liquid Nitrogen Karbogaz, Turkey - 
McCoy’s 5A Medium Biological Industries, Israel 01-075-1 
Methanol Riedel-de-Haén, Germany 24229 
N- Acetyl-L-Cystein Sigma  
Nonyl phenoxylpolyethoxylethanol Sigma, Germany 13021 
Penicillin/Streptomycin Solution Biological Industries, Israel - 
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Phenylmethanesulphonylfluoride Sigma, Germany P7626 
Phosphate Buffered Saline Sigma, Germany P4417 
Potassium Chloride Fluka, Switzerland 60129 
Protease Inhibitor Cocktail tablets Roche, Germany 11697498001 
Protein G Sepharose   
Sodium Chloride Riedel-de-Haén, Germany 13423 
Sodium Dodecyl Sulphate Sigma, Germany L4390 
Sodium Hydroxide Merck, Germany 106462 
Tetramethylethylenediamine Sigma, Germany T7029 
Thiobarbituric Acid   
Trichloroacetic Acid   
Tween®20 Merck, Germany 822184 
Developer   
Fixer   
Calcium Chloride   
Potassium Diphosphate   
Disodium Phosphate Dodecahydrate   
Disodium Phosphate   
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APPENDIX C: Molecular Biology Kits 
Name Supplier 
Catalog 
Number 
MTT Cell Proliferation Kit Roche, Germany 1465007-001 
Annexin-V-Fluos Stain Kit Roche, Germany 11988548001 
M30-Apoptosense® ELISA Peviva, Sweden PE0024 
CytoTox96® Non-Radioactive Cytotoxicity Assay Promega, USA G1780 
OxyBlot™ Protein Oxidation Detection Kit Chemicon Int., USA S7150 
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APPENDIX D: Laboratory Equipment 
Autoclave: Hirayama, Hiclave HV-110, JAPAN 
Certoclav, Table Top Autoclave CV-EL-12L, AUSTRIA 
Balance: Sartorius, BP211D, GERMANY 
Sartorius, BP221S, GERMANY 
Sartorius, BP610, GERMANY 
Schimadzu, Libror EB-3200 HU, JAPAN 
Centrifuge: Eppendorf, 5415C, GERMANY 
Eppendorf, 5415D, GERMANY 
Eppendorf, 5415R, GERMANY 
Kendro Lab. Prod., Heraeus Multifuge 3L, GERMANY 
Hitachi, Sorvall RC5C Plus, USA 
Hitachi, Sorvall Discovery 100 SE, USA 
Deepfreeze: -70o C, Kendro Lab. Prod., Heraeus Hfu486 Basic, GERMANY  132 
-20o C, Bosch, TURKIYE 
Distilled Water: Millipore, Elix-S, FRANCE 
Millipore, MilliQ Academic, FRANCE 
Electrophoresis: Biogen Inc., USA 
Ice Machine: Scotsman Inc., AF20, USA 
Incubator: Memmert, Modell 300, GERMANY 
Memmert, Modell 600, GERMANY 
Laminar Flow: Kendro Lab. Prod., Heraeus, HeraSafe HS12, GERMANY 
Magnetic Stirrer: VELP Scientifica, ARE Heating Magnetic Stirrer, ITALY 
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VELP Scientifica, Microstirrer, ITALY 
Microliter Pipette: Gilson, Pipetman, FRANCE 
Mettler Toledo, Volumate, USA 
pH meter: WTW, pH540 GLP MultiCal®, GERMANY 
Power Supply: Biorad, PowerPac 300, USA 
Refrigerator: 4˚C, Bosch, TÜRKiYE 
Shaker: Forma Scientific, Orbital Shaker 4520, USA 
GFL, Shaker 3011, USA 
New Brunswick Sci., Innova™ 4330, USA 
Spectrophotometer: Schimadzu, UV-1208, JAPAN 
Water bath: Huber, Polystat cc1, GERMANY 
BD Biosciences FACS Canto Flow Cytometer 
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APPENDIX E: Materials otherwise needed  
PVDF membrane   
Whatman paper   
Culture plates   
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APPENDIX F: Methods 
F.1. There have been four parameters in this study, enabling a broader view of the outcome 
of CDDP treatment according to presence or absence of TP53 gene thus presence (wt) or 
absence (p53-/-) of p53 protein, concentration of CDDP, absence or presence of NAC pre-
treatment and duration of CDDP treatment. The scheme below shows these parameters in 
detail. 
 
Fig F.1. Parameters of this work. Below are given the various values they were addressed to 
throughout the study.  
F.2. Cell Culture and Treatments 
After growth at >90% confluency of cells the medium was removed and the monolayer of 
cells attached on the culture dish/flask was washed with 1X sterile PBS. Following removal of 
the PBS, 1X sterile Trypsin solution was applied and the dish/flask was kept in the incubator 
for 5 to 10min until the cells were detached. The trypsinization process was ended by the 
addition of complete medium atop. The resulting cell suspension was examined for its cell 
density by the use of a hematocytometer under light microscope.  
There are two counting chambers in a hematocytometer. Each contains nine fields and five of 
these nine are to be examined for the number of cells on them. The counting is performed by 
taking the cells on the top and left grids which touch the middle line and all in the central 
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area. So 2 x 5 = 10 fields give the number of cells in 1µl of cell suspension. For the cell 
density per ml of cell suspension the former needs to be multiplied by 103. 
 
Fig. F.2. Schematic representation of a counting chamber on a hematocytometer. The area is 
divided into nine equal squares, five of which as depicted above are employed for counting. 
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100mm 
dish 
60mm 
dish 
35mm 
dish 
T25 
flask 
T75  
flask 
96 well 
plate 
12 well 
plate 
6 well 
plate 
Number of 
cells seeded 
2.2x106 
to 
4.4x106 
0.9x106 
to 
1.8x106 
3.5x105 
to 
7x105 
1x106 
to 
2x106 
3x106 
to 
6x106 
1.2x104  
to 
2.4x104 
/ well 
1.5x105 
to 
3x105 / 
well 
4x105 
to 
8x105 / 
well 
Final 
volume of 
medium 
20ml 10ml 4ml 10ml 15ml 
200µl / 
well 
2ml / 
well 
4ml / 
well 
Volume of 
1X PBS 
used 
10 ml 5ml 3ml 5ml 8ml 
200µl / 
well 
1ml / 
well 
2ml / 
well 
Volume of 
1X 
Trypsin-
EDTA used 
8ml 3ml 2ml 3ml 5ml 
100µl / 
well 
500µl / 
well 
750µl / 
well 
 
Table F.2: Basic numbers in cell culturing for various culture equipment of different shape 
and surface area. The number of cells to be seeded depends on the nature and size of the cells 
and requirements of the experiment. Volume of medium, 1X PBS and 1X Trypsin-EDTA may 
vary according to current cell density, requirements of the experiment and practice. 
 
Stock cell suspensions were prepared whenever sufficient number of cells was excess. 
Optimally, 106 cells in a cell suspension of corresponding volume were centrifuged for 5min 
at 300g and at the end the supernatant was removed. The pellet was resuspended in 1ml FM 
and transferred into cryovials which are kept at -80˚C in a beaker containing isopropanol for a 
steady temperature decrease of 1˚C / min and then stored in liquid nitrogen until use. One 
such cryovial can be thawed and the content be suspended in medium at 37˚C where after 
enough time for the cells to attach the medium has to be replaced with fresh medium to get rid 
of the toxic DMSO from the freezing mixture. 
After growth at >60% confluency of cells, the medium was removed and CDDP was 
administered at pre-set final concentrations of 0 (control), 6, 12, 20, 30, 60 and 90µM in fresh 
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medium. Administration of NAC was performed an hour before the CDDP treatment at a final 
concentration of 0.5mM. The medium containing the drug and/or supplement was not 
removed until the end of the pre-set duration of the treatment. 
F.3. Assessment of Cell Viability via MTT Assay 
Both cell lines were seeded into flat bottom 96-well plates at a cell density per well given in 
the table above and the plates were kept in the incubator until attachment of cells. Upon 
removal of the initial medium, treatment was performed in a volume of 100µl of fresh 
medium per well for the pre-set duration. Afterwards, 10µl of MTT Labelling Reagent were 
added atop in each well to achieve a final concentration of 0.5mg/ml. The plate is then 
incubated at 37˚C and 5% CO2 for 4h in the incubator. Latterly, 100µl of 1X Solubilization 
Solution per well were added and the plates were again incubated, this time overnight. After 
this second incubation period, the wells were measured as samples for their absorbance at the 
wavelength of 550nm where a reference wavelength of 655nm is set prior to 
spectrophotometrical analyses. Data were interpreted as percent of relative cell viability by 
calculating the ratio of absorbance from treated samples times 100 to absorbance of control 
samples. 
F.4. Assessment of Apoptotic Response via Flow Cytometric Analyses by Annexin-V 
Labelling 
Both cell lines were seeded into 12-well plates at a cell density per well given in the table 
above and the plates were kept in the incubator until attachment of cells. Upon removal of the 
initial medium, treatment was performed in fresh medium for the pre-set duration. 
Afterwards, the medium from each well was discarded and after washing with adequate 
volume of 1X PBS 0.5ml of 1X Trypsin solution was added to detach the cells. The contents 
were collected into FACS tubes and some volume of complete medium was introduced to 
stop the trypsinization process. The tubes were then centrifuged for 5min at 300g and the 
supernatants were discarded. The pellets were resuspended in 0.5ml of PBS and the tubes 
were again centrifuged for 5min at 300g. The supernatants were again discarded and the 
pellets were resuspended in 100 µl of Annexin-V Incubation buffer to which 2 µl of Annexin-
V-Fluorescein which labels the exposed phosphotidylserines on cell surfaces as a marker of 
early apoptosis were added. The tubes were then kept in dark for 15min at room temperature. 
After a third turn of centrifugation for 5min at 300g the supernatants were discarded and the 
pellets were resuspended in 0.5ml of PBS. The suspensions were then analyzed by BD FACS 
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Diva. Data were interpreted as percentages of a certain population of a pre-set size which then 
were converted into folds with respect to the control values. 
F.5. Assessment of ROS Production via Flow Cytometric Analyses by DCFH-DA 
Labelling 
Both cell lines were seeded into 12-well plates at a cell density per well given in the table 
above and the plates were kept in the incubator until attachment of cells. Upon removal of the 
initial medium, treatment was performed in fresh medium for the pre-set duration. 
Afterwards, the medium from each well was discarded and after washing with adequate 
volume of 1X PBS 0.5ml of 1X Trypsin solution was added to detach the cells. The contents 
were collected into FACS tubes and some volume of complete medium was introduced to 
stop the trypsinization process. The tubes were then centrifuged for 5min at 300g and the 
supernatants were discarded. The pellets were resuspended in 0.5ml of PBS and the tubes 
were again centrifuged for 5min at 300g. The supernatants were again discarded and the 
pellets were resuspended in 100 µl of DCFH-DA Incubation Solution. The tubes were then 
kept in dark for 25min at room temperature. After a third turn of centrifugation for 5min at 
300g the supernatants were discarded and the pellets were resuspended in 0.5ml of PBS. The 
suspensions were then analyzed by BD FACS Diva. Data were interpreted as percentages of a 
certain population of a pre-set size which then were converted into folds with respect to the 
control values. 
F.6. Assessment of Lipid Peroxidation via TBARS Assay 
Both cell lines were seeded into 12-well plates at a cell density per well given in the table 
above and the plates were kept in the incubator until attachment of cells. Upon removal of the 
initial medium, treatment was performed in fresh medium for the pre-set duration. 
Afterwards, the medium from each well was discarded and 0.5ml of PBS was added to aid in 
cell harvesting by means of a scraper. The contents of each well were transferred into 
Eppendorf tubes. The wells were washed again with 0.5ml of PBS and the secondary contents 
were also collected in corresponding tubes. The tubes were then centrifuged for 5min at 300g. 
The supernatants were discarded and the pellets resuspended in 0.5ml of PBS. After a second 
turn of centrifugation for 5min at 300g the supernatants were discarded and 110 µl of 10% 
SDS were added atop the pellets and the tubes were frozen at -20˚C. After thawing, a third 
round of centrifugation took place at 4˚C for 10 min at 3000g. 10 µl of each supernatant was 
taken onto an ELISA plate for protein content assay. To the rest 200 µl of ice-cold TCA 
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Solution were added and the tubes were kept for 15min on ice. A fourth centrifugation was 
then performed at 4˚C for 15min at 2200g. In the meantime, standards were prepared as 
instructed. Latterly, into a second set of Eppendorf tubes 200µl of each standard and sample 
are transferred. Into each tube 200µl of TBA Solution were added and the tubes were heated 
on a heating block for 10min at 100˚C. After cooling the content of the tubes were measured 
as standards and samples for their absorbance at the wavelength of 550nm. Data were 
interpreted with respect to the data from the standards. 
F.7. Assessment of Protein Carbonylation via OxyBlot™ 
F.7.1. on Total Protein 
Both cell lines were seeded into dishes at a cell density per well given in the table above and 
the dishes were kept in the incubator until attachment of cells. Upon removal of the initial 
medium, treatment was performed in fresh medium for the pre-set duration. Afterwards, the 
medium from each dish was discarded and adequate volume of ice-cold 1X PBS was added to 
aid in cell harvesting by means of a scraper. The contents of each dish were transferred into 
tubes of adequate volume. The dishes were washed again with adequate volume of ice-cold 
PBS again and the secondary contents were also collected in corresponding tubes. The tubes 
were then centrifuged for 30Sec at 13200rpm. The supernatants were discarded and the pellets 
resuspended in adequate volumes of CLB. The tubes were then kept on ice for 30min. 
Subsequently, a second round of centrifugation was performed for 10min at 13200rpm. The 
supernatants were kept at -20˚C for shorter and at -80˚C for longer periods of time. 
Protein content assay procedure was performed according to manufacturer’s instructions. Into 
the wells of an ELISA plate, triplets or quadruplets of each sample of same or different 
dilutions with ddH2O were transferred in aliquots of 5µl. Triplets or quadruplets of BSA 
standards of concentration 0, 10, 5, 2.5, 1.25, 0.625 etc. are also transferred into other wells of 
the plate and atop of all wells 95µl of diluted Bradford Solution were added. The wells were 
measured as samples and standards for their absorbance at the wavelength of 595nm by the 
presence of a blank. Data were interpreted by using a BSA Standard Curve where its equation 
needs to have a R2 value larger than 0.9 and smaller than 1.0. 
OxyBlot™ procedure was performed according to manufacturer’s instructions. After 
performing a series of dilutions to bring each protein sample to the same concentration of the 
smallest value in the current pool of samples, corresponding volumes of each sample for 15 to 
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20 µq of total protein were taken into two sets of Eppendorf tubes and the volumes are 
completed to 5 µl with ddH2O. At this point, if fishing out of a certain protein from a total 
protein solution was formerly performed, regardless of the concentration of the protein in the 
immunoprecipitation product 5 µl aliquots of each sample were taken. To both sets of tubes 5 
µl of 12%SDS are added. Then, to one of the sets 10 µl of 1X DNPH Solution and to the 
other set 1X DC Solution were added. After incubation of the tubes for 15min at room 
temperature, in both sets 7.5 µl of Neutralization Solution were added. Addition of certain 
amount of 1X Gel Loading Buffer for OxyBlot™ does not affect the electrophoresis in any 
way.  
SDS-PAGE Gels were prepared according to the instructions of the equipment’s 
manufacturer. Fresh separating gel solution was poured in between the two glass panes which 
prove a vacancy of 1mm thickness and overlaid by a layer of isopropanol to stop contact with 
air. Once the separating gel was cast and set, the isopropanol layer was removed and the 
contact areas washed with ddH2O. The stacking gel solution was then poured atop. This time 
instead of the isopropanol layer a comb of desired well number was placed sealing the air 
contact areas. Once the stacking gel was set, the comb was removed. Treated samples, 
negative controls and if empty wells available mixture of standard proteins attached DNP 
residues with or without addition of gel loading buffer were transferred into the wells in all 
cases without heating prior to loading. The gels were run in 1X RB for about 2h at room 
temperature with a constant voltage of 70V.  
Once the gels were run, the proteins were transferred onto MetOH activated PVDF 
membranes, by means of electricity. The assemblies consisting of a sponge, Whatman paper, 
gel, PVDF membrane, a second layer of Whatman paper and a second sponge were immersed 
in 1X TB prior to alignment with respect to the direction of electricity. A constant current of 
110mA was applied for 2h at room temperature by the presence of an ice-block to overcome 
the increasing temperature in time. After the transfer the membranes were blocked in 1X 
Blocking/Dilution Buffer for 2h at room temperature. The blots were then incubated with the 
1˚Ab Solution specific for derivatized sites on the proteins overnight in cold room with gentle 
shaking. Subsequently, the blots were rinsed twice, washed once for 15min and then twice for 
5min with 1X PBS-T with gentle shaking at room temperature. They were then incubated 
with 2˚Ab Solution specific for 1˚Ab overnight in cold room with gentle shaking. Afterwards, 
they again were rinsed twice, washed once for 15min and then twice for 5min with 1X PBS-T 
with gentle shaking at room temperature and kept in cold 1X PBS-T until detection. 
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The blots were drained from excess PBS-T and placed on to a layer of plastic film in a 
cassette with their protein-carrying sides up. Atop the freshly prepared mixture of 
chemiluminescent reagents was applied and a second layer of plastic film was overlaid so that 
the more sensitive X-Ray film does not come into contact with the liquids. The light emitted 
changes the film in a way that after immersing the film into the Developer Solution, 
subsequent rinsing in water, immersing into the Fixer Solution and a final rinsing in water the 
areas exposed to light yield darker bands than the background. In this sense, the detection of 
carbonylated proteins in the samples was performed. 
F.7.2. on Immunoprecipitates 
Firstly, from the least concentrated in the current pool of protein isolates the highest possible 
amount of protein for a final volume of 600µl was calculated. This enabled highest protein 
yields after fishing out a certain protein. Usually, the amount of protein was around 800µg. 
The more concentrated samples, on the other hand, were diluted with CLB to give the final 
volume of 600µl in each Eppendorf tube. Into all tubes 1µl (≡1µg) of capture Ab was added 
and they were mixed gently at room temperature. In the meantime, 30µl per tube of 50% 
slurry Protein G Sepharose suspension were taken in an Eppendorf tube and centrifuged for 
30sec at 13200rpm at room temperature. The supernatant was discarded and the pellet 
resuspended in starting volume of cold CLB. This process was repeated five times and at last 
the pellet was resuspended in adequate volume of CLB. From this suspension 30µl were 
transferred into each tube and kept overnight in cold room with gentle shaking. Afterwards, 
the tubes were centrifuged for 30sec at 13200rpm at 4˚C and the supernatants were discarded. 
The pellets were resuspended either with 5µl of CLB or 1X Gel Loading Buffer for 
OxyBlot™ and pipetted up and down for about 5min to separate protein complexes from the 
beads mechanically as heating of samples prior to loading is not allowed in the OxyBlot™ 
procedure. The tubes were then centrifuged for 1min at 13200rpm at room temperature and 
supernatants were treated as protein samples in the OxyBlot™ procedure. 
 
 
 
